1

RESUME OF DOMINIQUE BELPOMME

Professor in Clinical Oncology at the Paris University René Descartes

Funding President of the Association for Research and Treatments Against Cancer

ARTAC

2

3

Dominique BELPOMME Born on 14 March 1943 in ROUEN, France ARTAC Married, two children 57-59 rue de la convention 75015 PARIS Phone: +33 (0)1 45 78 53 54 Fax: +33 (0)1 45 78 53 50 Email: artac.cerc@gmail.com

EXPERIENCE AND EDUCATION CAREER IN UNIVERSITY HOSPITALS • 2009: Medical Oncologist in the Clinical center Alleray-Labrouste, Paris • 2001: Medical Oncologist in the European Hospital Georges Pompidou (HEGP), Paris • 1997: Full Professor – Board Certified Specialist in Clinical Oncology at the Paris University, Paris • 1995: Head of the Clinical Oncology department in the Boucicaut Hospital, Paris • 1984: Assistant Professor in Clinical Oncology at the Bichat University Hospital Center, Paris • 1975: Resident in Clinical Oncology at the Gustave Roussy Institute, Villejuif (Pr.Georges Mathé), then

at the Lariboisière St Louis University Hospital Center, Paris (Pr. Michel Boiron) • 1968: Resident in Clinical Oncology and research fellow at the Roswell Park Memorial Institute, Buffalo,

NY, USA (Pr. G.E. Moore) • 1967: Internship in the Paris University Hospitals, Paris • 1964: Honour student in the Paris University Clinical Clerkship, Paris EDUCATION • 1980: Speciality in Clinical Oncology, Paris VII University, Faculty of Medicine • 1975: M.D. Thesis, Paris University, Faculty of Medicine • 1971: Master’s degree in Cellular Biology, Pierre & Marie Curie Paris University, Faculty of Sciences • 1969: Advanced course in Experimental Oncology, Paris Sud University • 1961: Certificate of Physics, Chemistry and Natural Sciences, Paris VI University, Faculty of Sciences RESEARCH GROUPS • 2005: Scientific Adviser for the European Spatial Agency (ESA) – Melissa Project • 2004: Scientific Adviser for the European Commission (project: Science, Children, Awareness, Legal

instrument, Evaluation – SCALE), Brussels • 2003: Operations Manager for the implementation of the French National Cancer Plan • 1999: Vice president of the section of Life sciences of the French Association for the Advance in

Sciences (AFAS), founded by Claude Bernard, Paris • 1991: Visiting research fellow at the National Cancer Institute (NCI), Bethesda, USA • 1989: Member of the European Organization for Research and Treatments on Cancers (EORTC) • 1986: Director and Founder of the Evaluation and Research Centre on Cancer (CERC) of the ARTAC,

Paris • 1984: President and Founder of the French Association for Research on Treatments Against Cancer

(ARTAC), Paris, up to now • 1979: Prize winner of the French Academy of Medicine for work on the Reed Sternberg cell • 1970: Director of the Laboratory of Cellular Biology and Tumoral Immunology at the Cancerology and

Immuno-Genetics Institute (Pr. G. Mathé), Villejuif • 1969: Research fellow at the Roswell Park Memorial Institute (RPMI), Buffalo, NY, USA • 1968: Research fellow of the International Agency for Cancer Research (IARC), Lyon

4

• 1967: Research fellow of the French National Center for Scientific Research (CNRS) at the Cancerology and Immuno-Genetics Institute (ICIG), Villejuif

SCIENTIFIC SOCIETIES • American Society for Clinical Oncology (ASCO) • American Association for Cancer Research (AACR) • European Society for Medical Oncology (ESMO) • Société Française du Cancer (SFC), French Cancer Society • Association pour la Recherche Thérapeutique Anti-Cancéreuse (ARTAC), Association for Research and

Treatments Against Cancer • New York Academy of Sciences • Association Française pour l'Avancement des Sciences (AFAS), French Association for the Advancement

of Science

5

PUBLICATIONS BOOKS AND JOURNALS 1. As the author

• D. BELPOMME. Avant qu’il ne soit trop tard , Fayard Ed., 2007. • D. BELPOMME. Guérir du cancer ou s'en protéger, Fayard Ed., 2005. Translated into Italian, 2009. • D. BELPOMME. Ces maladies créées par l’homme. Comment la dégradation de notre

environnement met en péril notre santé, Albin Michel Ed., 2004. • D. BELPOMME. Les grands défis de santé publique en France et en Europe, La Librairie Médicis

Ed., 2003. • D. BELPOMME. Cancérologie Générale, J.B. Baillière Ed., 1979, p. 353. 2. As a contributor

• P. GODEAU. Traité de Pathologie Générale, Tome I, Flammarion Ed., 1981. Re-edited, 1987.

• G. MATHE. Cancer active immunotherapy. Immunoprophylaxy and immunorestauration. Recent results in cancer research n°55, Springer Verlag Ed., Berlin-Heidelberg, 1976.

3. As the coordinator

• Cancer and the environment, Biomedicine and Pharmacotherapy, 2007. • New drug design and development in cancer, Cancer Chemotherapy and Pharmacology, 1993. • Les adénocarcinomes de l'ovaire, Bulletin du Cancer, 1993. • Les traitements médicaux du cancer, Médecine/Sciences, 1991. • La chimiothérapie des cancers, Bulletin du Cancer, 1991. • Les nouveaux médicaments et nouvelles stratégies développées en France pour le traitement des

cancers et du SIDA. Report of the second workshop of the ARTAC on therapeutic experiment organised by ARTAC Cancer Communication, 1990.

• Les Bonnes Pratiques Cliniques en Cancérologie. Report of the first workshop of the ARTAC on therapeutic experiment organised by ARTAC Cancer Communication, 1988.

SCIENTIFIC ARTICLES (with peer review commettee) 1. D. BELPOMME, P. IRIGARAY. Is the growing incidence of prostate cancer only due to overdiagnosis?

JNCI, 2009 (Submitted for publication). 2. P. IRIGARAY, D. BELPOMME . Mechanism of Environmental Carcinogenesis. MS number 32 in

Encyclopedia of Environmental Health. Elsevier, 2010, In press (Invited publication).

3. P. IRIGARAY, D. BELPOMME . Adipose tissue as a key contributor to Polycyclic Aromatic Hydrocarbon-induced carcinogenesis. In Polycyclic Aromatic Hydrocarbons: Pollution, Health Effects and Chemistry. Novascience Publisher, 2009, In press (Invited publication).

4. P. IRIGARAY, D. BELPOMME . Basic properties and molecular mechanisms of exogenous chemical carcinogens. Carcinogenesis, 2009, doi:10.1093/carcin/bgp252 (Invited publication).

5. M. LANDAU-OSSONDO, N. RABIA, J. JOS-PELAGE, L.M. MARQUET, Y. ISIDORE, C. SAINT-AIME, M. MARTIN, P. IRIGARAY, D. BELPOMME . Why pesticides could be a common cause of prostate and breast cancers in the French Caribbean Island, Martinique. An overview on key mechanisms of pesticide-induced cancer. Biomed. Pharmacother., 2009, 63: 383-395.

6. D. BELPOMME , P. IRIGARAY, M. LANDAU-OSSONDO, M. MARTIN. The growing incidence of prostate cancer in the French Caribbean islands, Martinique and Guadeloupe: A possible causal role of pesticides. Int. J. Oncol., 2009, 35: 433.

7. P. IRIGARAY, S. LACOMME, L. MEJEAN, D. BELPOMME . Ex vivo study of incorporation into adipocytes and lipolysis-inhibition effect of polycyclic aromatic hydrocarbons. Toxicol. Letters, 2009, 187: 35-39.

8. D. BELPOMME , P. IRIGARAY, M. OSSONDO, D. VACQUE, M. MARTIN. Prostate cancer as an environmental disease: an ecological study in the French Caribbean islands, Martinique and Guadeloupe. Int. J. Oncol., 2009, 34: 1037-1044.

6

9. D. BELPOMME , P. IRIGARAY, L. HARDELL. Electromagnetic fields as cancer-causing agents. Environ. Res., 2008, 107: 289-290.

10. P. IRIGARAY, JA. NEWBY, S. LACOMME, D. BELPOMME . Overweight/obesity and cancer genesis: More than a biological link. Biomed. Pharmacother., 2007, 61: 665-678.

11. D. BELPOMME , P. IRIGARAY, L. HARDELL, R. CLAPP, L. MONTAGNIER, S. EPSTEIN, AJ. SASCO. The multitude and diversity of environmental carcinogens. Environ. Res., 2007, 105: 414-429.

12. P. IRIGARAY, J.A. NEWBY, R. CLAPP, L. HARDELL, V. HOWARD, L. MONTAGNIER, S.S. EPSTEIN, D. BELPOMME . Lifestyle-related factors and environmental agents causing cancer: An overview. Biomed. Pharmacother., 2007, 61: 640-658.

13. D. BELPOMME , P. IRIGARAY, J.A. NEWBY, V. HOWARD, R. CLAPP, A.J. SASCO, L. HARDELL. The growing incidence of cancer: Role of lifestyle and screening detection. Int. J. Oncol., 2007, 30: 1037-1049.

14. D. BELPOMME . The contribution of the physico-chemical environment to the genesis of cancer: What extent and how to measure it? Bull. Mem. Acad. R. Med. Belg., 2005, 160: 163-180.

15. D. BELPOMME , I. KRAKOWSKI, M. BEAUDUIN, T. PETIT, J.L. CANON, J. JANSSENS, S. GAUTHIER, A. DE PAUW, V. MOREAU, L. KAYITALIRE. Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: A phase II study. Gynecol. Oncol., 2003, 91(1): 32-38.

16. X. PIVOT, S. WADLER, C. KELLY, R. RUXER, J. TORTOCHAUX, J. STERN, D. BELPOMME , Y. HUMBLET, C. DOMENGE, N. CLENDENINN, A. JOHNSTON, C. PENNING, M. SCHNEIDER. Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer. Ann. Oncol., 2001, 12(11): 1595-1599.

17. D. BELPOMME , S. GAUTHIER, E. PUJADE-LAURAINE, T. FACCHINI, M.J. GOUDIER, I. KRAKOWSKI, G. NETTER-PINON, M. FRENAY, Ch. GOUSSET, F.N. MARIE, M. BENMILOUD, F. STURTZ. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann. Oncol., 2000, 11(11): 1471-1476.

18. D. BELPOMME . Why and how new directions should be taken in cancer treatment research. EPC, 1999, p.38-40.

19. D. BELPOMME . Development of Drugs for Cancer Treatment in France. EPC, 1998, p.112-119. 20. J. TROTOUX, V. BASSOT, D. AIDAN, D. BELPOMME . Chimiocurabilité d’un sous-groupe de

malades atteints de cancers ORL épidermoïdes exclusivement traités par chimiothérapie de type Cisplatine-5-Fluorouracil (P-FU) pour leur tumeur primaire : analyse rétrospective d’une cohorte de 111 cas. Annales d’ORL, Paris, 1997.

21. J.F. GILLETTE, C. FERME, N. MOISY, L. MIGNOT, R. SCHACH, J.R. VIGNAUX, J.G. BESNER, G. CAILLE, D. BELPOMME . Double-blind crossover clinical and pharmcokinetic comparison of oral morphine syrup and sustained release morphine sulfate capsules in patients with cancer-related pain. Clin. Drug Invest., 1997, 14: 22-27.

22. V. DE PARADES, J.M. CHEVALLIER, J.P. BLANCHE, B. PATRI, O. HURTIER, D. BELPOMME , F. VILDE, A. WKOWIK. Adenocarcinoma of the jejunum: diagnostic value of push-type enteroscopy. A case report. Acta Endoscopica, 1996, 26: 301-305.

23. D GEDOUIN, P PESPREZ, JJ PERRON, F FLEURY, G LECLECH, L MIGLIANICO, D. BELPOMME , C CHENAL. Cancers de la base de langue et de l’hypopharynx : résultats d’un essai multicentrique randomisé de chimiothérapie avant traitement locorégional. Bull. Cancer/Radiother., 1996, 83: 104-107.

24. G. KEMP, P. ROSE, J. LURAIN, M. BERMAN, A. MANETTA, B. ROULLET, H. HOMESLEY, J. GLICK, D. BELPOMME . Treatment of ovarian cancer patients with stage III-IV with Cisplatine and Cyclophosphamide in Amifostine protection. J. Clin. Onc., 1996, 14: 2101-2112.

25. J.L. MISSET, M. DI PALMA, M. DELGADO, R. PLAGNE, P. CHOLLET, P. FUMOLEAU, B. LE MEVEL, D. BELPOMME , J. GUERRIN, P. FARGEOT, et al. Adjuvant treatment of node positive breast cancer with Cyclophosphamide, Adriamycine, 5-Fluorouracil and Vincristine versus Cyclophosphamide methotrexate and 5-Fluorouracil. Final report after 15 years median follow-up. J. Clin. Onc., 1996, 14: 1136-1145.

26. B. DAUTZENBERG, C. CHASTANG, R. ARRIAGADA, T. LE CHEVALIER, D. BELPOMME . Post-operative radiotherapy versus combined chemotherapy (COPAC) and radiotherapy in resected non small cell lung carcinoma: A randomized trial on 267 patients. Cancer, 1995, 76: 779-786.

27. C. CALABRESSE, L. VENTURINI, G. RONCO, P. VILLA, L. DEGOS, D. BELPOMME , C. CHOMIENNE. Selective induction of apoptosis in myeloid leukemic cell lines by monoacetone glucose-3 butyrate. Biochem. Biophys. Res. Com., 1994, 201: 266-283.

7

28. C. CALABRESSE, L. VENTURINI, G. RONCO, P. VILLA, C. CHOMIENNE, D. BELPOMME . Butyric acid and its monosccharide ester induce apoptosis in the HL-60 cell line. Biochem. Biophys. Res. Com., 1993, 195: 31-38.

29. D.G. ALLEN, J. BAAK, D. BELPOMME , J.S. BEREK, K. BERTELSEN, W.W. TEN BOKKEL HUININK, M.E. VAN DER BURG, A.H. CALVERT, P.F. CONTE, J. DAUPLAT, et al. Advanced epithelial ovarian cancer: 1993 consensus statements. Ann. Oncol., 1993, 4 (suppl 4): 83-88.

30. J.B. VERMORKEN, W.W. TEN BOKKEL HUININK, E.A. EISENGAUER, S. PECORELLI, D. BELPOMME , P. CONTE, S.B. KAYE. Carboplatin versus cisplatin in ovarian carcinoma. Ann. Oncol., 1993, 4 (suppl 4): 41-48.

31. P. WORKMAN, D. BELPOMME , J. ROBERT. New drug design and development in cancer: present status and future perspectives. Editorial. Cancer Chemother. Pharmacol., 1993, 32: 83-84.

32. D. BELPOMME , M.H. FILIPPI, M. LE BONNIEC, F. HERITIER. Les adénocarcinomes de l’ovaire, en tant que modèle d’étude des cancers et de leurs traitement. Editorial. Bull. Cancer, 1993, 80: 115-120.

33. D. BELPOMME . Chimiothérapie anti-cancéreuse : vers un transfert des concepts de la biologie à la recherche clinique. Bull. Cancer, 1991, 78: 1097-1103.

34. D. BELPOMME . Traitements médicaux des cancers : les nouvelles voies. Médecines/Sciences, 1991, 7: 440-442.

35. G. PINON, M.C. PINEL, M.J. GOUDIER, B. COIFFIER, M.H. FILIPPI, A. GOUPIL, B. ROULLET, T. FACCHINI, L. MIGNOT, P. TRESCA, M. DELGADO, D. BELPOMME . Etude de la Vinorelbine (V) associée à l’Héxaméthylmelamine (H) dans les adénocarcinomes de l’ovaire : résultats préliminaires d’un essai phase I-II A, NHO-88, du groupe "ovaire" de l’ARTAC. Bull. Cancer, 1991, 78: 1119-1131.

36. D. BELPOMME . Diversité des mécanismes de résistance aux chimiothérapies anti-cancéreuses. Médecine/Sciences, 1991, 7: 465-472.

37. B. ROULLET, G. PINON, M.J. GOUDIER, B. COIFFIER, MH. FILIPPI, A. GOUPIL, T. FACCHINI, L. MIGNOT, P. TRESCA, MC. PINEL, P. HIS, M.DELGADO, D. BELPOMME . Intérêt de l’association Vinorelbine-Hexamethyl-Melamine (V-H) dans le traitement des adénocarcinomes ovariens évolués. Résultats préliminaires d’une étude phase I-II, NHO-88 du groupe "ovaire" de l’ARTAC. Gynécologie, 1990, 41: 391-399.

38. D. BELPOMME , F. HERITIER. New drugs and therapeutic strategies in Cancer and AIDS. Cancer Communication, 1990, 4: 133-144.

39. D. BELPOMME , J.P. DROZ, F.N. MARIE, M. NAMER, THU NGUYEN TAN, A. PECKING, J. ROUESSE et D. VANEL. Réponse des métastases osseuses aux thérapeutiques médicales : définition des critères d’évaluation et essai de classification. Bull. Cancer 1989, 76, 273-289.

40. Ph. MARTIN, R. BUGAT, G. PINON, MC. PINEL, F. HERITIER, M. CHAZARD, M.C. DELESTRAIN, D. BELPOMME . 300 mg/m¨ Carboplatin (Cb) Adriamycin (A) Cyclophosphamide (C) in advanced ovarian carcinoma. Cancer Chemother. Pharmacol., 1989, 23: 331-332.

41. R. BUGAT, M.C. PINEL, Ph. MARTIN, G. NETTER-PINON, D. BELPOMME . Apport du Carboplatine dans le traitement des adénocarcinomes ovariens de stade FIGO III-IV. Etude de faisabilité de la combinaison CACb-300 (Cyclophosphamide, adriamycine, carboplatine). Gynécologie, 1988, 39: 191-196.

42. D. BELPOMME , C. GISSELBRECHT, M. MARTY, M.H. FILIPPI, K. HACENE, P. BOUFFETTE, et al. Les cancers du sein métastasés sont-ils potentiellement curables par chimiothérapie ? Etude d’une nouvelle combinaison (VMMc) associant Vindésine, Mitoxantrone et Mitomycine C. Gynécologie, 1988, 39: 197-204.

43. D. BELPOMME , C. GISSELBRECHT, M. MARTY, K. HACENE, M.H. FILIPPI, G. MICHAUD, P. BOUFFETTE, G. NETTER-PINON, E. PUJADE-LAURAINE, L. MIGNOT, D. GEORGE, J. MARAL. Traitement des cancers du sein métastasés par la combinaison VMMc (Vindésine, Mitoxantrone, Mitomycine C) : incidence sur le pronostic et étude des résistances croisées par rapport aux traitements antérieurs. Compte-rendus thérapeutiques, 1987, 5: 3-25.

44. D. BELPOMME , V. COUR, C. GISSELBRECHT, A. LE ROL, L. MIGNOT, M. MARTY, J. MARAL. Longues rémissions induites par la chimiothérapie dans les cancers du sein métastasés : valeur de l’association Mitoxantrone, Eldésine et Mitomycine C (MEM). Nouv. Presse Med., 1987, 16: 635.

45. D. BELPOMME , F. HERITIER, C. GISSELBRECHT, M. MARTY, G. MICHAUD, A. LE ROL, D. GEORGE, J. MARAL. Long duration of response with Vindesine-Mitoxantrone-Mitomycin C (VMMc) combination chemotherapy in metastatic breast cancer: A pilot phase II study. Cancer Treat. Rep., 1987, 71: 845-847.

46. G. MATHE, J.L. MISSET, R. PLAGNE, P. REIZENSTEIN, D. BELPOMME , B. LE MEVEL, J. GUERRIN, P. FUMOLEAU, R. METZ, M. DELGADO, et al. Adriamycin, Vincristine,

8

Cyclophosphamide and 5-Fluorouracil (AVCF) compared with Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) in premenopausal breast carcinoma. Drugs Exptl. Clin. Res., 1986, 12: 143-145.

47. D. BELPOMME , A. LE ROL, F. PAPPO, J. BERNHEIM, B. DAUTZENBERG, J.M. BRECHOT, C. CHASTANG, R.A. GUERIN. Evaluation de la qualité de vie chez les malades atteints de cancer : premières applications aux cancers bronchiques évolués. Bull. Cancer, 1986, 73: 627-633.

48. C. GISSELBRECHT, L. MIGNOT, E. LEPAGE, D. BELPOMME , F. MORVAN, M. MARTY. Stratégie thérapeutique dans les adénocarcinomes de l’ovaire. Contracept. Fert. Sex., 1984, 12 (suppl 12): 315.

49. J.C. MISSET, M. DELGADO, R. PLAGNE, D. BELPOMME , et al. Five years results of the French adjuvant trial for breast cancer comparing CMF to the combination of Adriamycin, Vincristine, Cyclophosphamide and 5-Fluorouracil. In "Adjuvant therapy of cancer IV", Eds. Grune and Stratton, Jones SE, Salomon SE, Orlando, 1984, p.243-251.

50. D. BELPOMME , F. PAPPO, A. LE ROL, P. SIBELLA, F. MANCILLA, R. MISSONIER, A. BOHU, J.C. THALABARD, M. ROBIN, J. SENEZE, et al. Chimiothérapie des adénocarcinomes de l’ovaire : bilan des dix dernières années, nouveaux concepts et place dans la stratégie thérapeutique d’ensemble. Contracept. Fert. Sex., 1984, 12 (suppl 12): 303-313.

51. L. MIGNOT, M. ESPIE, F. MORVAN, A. DE ROQUANCOURT, D. BELPOMME , A. GORINS, M. MARTY. Cancer du sein en poussée évolutive. Expérience du groupe St-Louis-Beaujon. A propos de 71 cas. Gynécologie, 1984, 35: 175-180.

52. H. GAUTIER, D. BELPOMME , M. ZAEGEL, J.P. BENOIT, P.Y. PALEY, C. BERTRAND, J.R. MAURY, P. MALAMUD, C. NEUMANN. Les adénocarcinomes bronchiques : réévaluation clinique et résultats thérapeutiques actuels. Ouest Méd., 1983, 36: 767-771.

53. L. MIGNOT, D. BELPOMME , M. ESPIE, F. MORVAN, Ph. CLOT, C. MAYLIN, A. GORINS, M. MARTY. Les cancers inflammatoires du sein. Contracep. Fert. Sex., 1983, 11 (suppl 11): 531-535.

54. C. GISSELBRECHT, F. CALVO, L. MIGNOT, E. PUJADE-LAURAINE, M. BOUVRY, O. DANNE, D. BELPOMME , M. MARTY. Fluorouracile (F), Adriamycin (A), and Cis-platin (P), (FAP) combination chemotherapy of advanced esophageal carcinoma. Cancer, 1983, 52: 974-977.

55. D. BELPOMME , H. GAUTIER, Cl. CHASTANG. Cancers bronchiques primitifs inopérables : traitement par des combinaisons chimiothérapiques incluant le Cis-platinum. Nouv. Presse Méd., 1983, 12: 2671-2675.

56. J. WYBRAN, B. SERROU, D. BELPOMME , et al. Immunomodulating of T cell and NK function by NPT 15392 in cancer patients. A cooperative study by the tumor immunology group. In "Current concepts in tumor immunology and cancer immunotherapy" (B. Serrou, C. Rosenfeld and J. Daniels), Ed. Elsevier/ North Holland Publ., 1982.

57. A.GISSELBRECHT, F. CALVO, L. MIGNOT, E. PUJADE-LAURAINE, M. BOUVRY, O. DANNE, D. BELPOMME , F. MORVAN, M. MARTY. Traitement de cancers épidermoïdes évolués de l’oesophage par l’association 5 Fluorouracile, Adriamycine et Cis-Platinum. Nouv. Presse Med., 1982, 11: 1859-1862.

58. D. BELPOMME , L. MIGNOT, M. GRANDJEAN, E. PUJADE-LAURAINE, A. LE ROL, C. GISSELBRECHT, M. MARTY, M. BOIRON. Prévention de l’alopécie des chimiothérapies anticancéreuses par hypothermie du cuir chevelu. Nouv. Presse Med., 1982, 11: 929.

59. D. BELPOMME , M. MARTY, C. GISSELBRECHT, L. MIGNOT. Immunothérapie des cancers : réalité ou fiction ? Path. Biol., 1981, 29: 179-188.

60. D. BELPOMME , P. SIBELLA, J. SENEZE, J. BARRIER, M. LEVARDON, M. ROBIN, N. VIGNERON, A. LEROL. Facteurs de pronostic et traitement des cancers de l’ovaire : résultats de plusieurs protocoles de chimiothérapie. Gynécologie, 1981, 32: 367-372.

61. E. PUJADE-LAURAINE, D. BELPOMME , G. MATMHE, A.J.S. DAVIES. Nuclear convolutions and immunological membrane markers in non-Hodgkin lymphoblastic lymphoma. Lancet, 1980, 1: 492.

62. C. MICHEAU, A. BERNARD, E. PUJADE-LAURAINE, D. BELPOMME , C. CARLU, B. CLAUSSE. Lymphomes malins non Hodgkiniens : fiabilité du "typage" par les marqueurs cyto-enzymatiques. Nouv. Presse Med., 1980, 9(3): 167-170.

63. D. BELPOMME , L. SCHWARZENBERG, A. BOHU, D. DHERMY, J.F. BERNARD, A. LEROL, E. PUJADE-LAURAINE, M. BAYSSAS, J.R. BOULERLIQUE, Ph. F. BERNARD. Administration de Vincaleucoblastine à fortes doses dans les cancers de l’ovaire évolués : Résultats préliminaires d’un essai thérapeutique phase II portant sur 12 malades. Rev. Franç. Gynécol., 1979, 74: 597-601.

64. D. BELPOMME , A. BOHU, P. SIBELLA, A. LEROL, M. MUSSET, E. PUJADE-LAURAINE, C. BERSAY, P. MARLAND. 102 cas de cancers primitifs de l’ovaire traités depuis 1974 : III - Les associations chimiothérapiques, intérêt d’un protocole (0E-O5) bicyclique séquentiel combinant 7 médicaments anticancéreux. Rev. Franç. Gynécol., 1979, 74: 587-596.

9

65. M. LEVARDON, P. SIBELLA, D. BELPOMME , H. IRONDELLE, N. VIGNERON, M. ROBIN, J. BARRIER et J. SENEZE. 102 cas de cancers primitifs de l’ovaire traités depuis 1974 : II - Place et rôle de la chirurgie de réduction et intérêt des interventions de contrôle. Rev. Franç. Gynécol., 1979, 74: 577-585.

66. P. SIBELLA, D. BELPOMME , M. LEVARDON, A. BOHU, J. BARRIER et J. SENEZE. 102 cas de cancers primitifs de l’ovaire traités depuis 1974 : I - Les facteurs de pronostic. Rev. Franç. Gynécol., 1979, 74: 569-576.

67. M. BAYSSAS, J. GOUVEIA, P. RIBAUD, M. MUSSET, F. DE VASSAL, J.L. PICO, L. DE LUCA, J.L. MISSET, D. MACHOVER, D. BELPOMME . Phase II trial with Vindesine for regression induction in patients with leukemias and hematosarcomas. Cancer Chemother. Pharmacol., 1979, 2: 247-255.

68. J. ETIEMBLE, J.F. BERNARD, Ch. PICAT, D. BELPOMME , P. BOIVIN. Red blood cell enzyme abnormalities in patients treated with chemotherapy. Brit. J. Hematology, 1979, 42 : 391-398.

69. G. MATHE, F. DE VASSAL, L. SCHWARZENBERG, M. DELGADO, R. WEINER, M.A. GIL, J. PENA-ANGULO, D. BELPOMME , P. POUILLART, D. MACHOVER, et al. Preliminary results of three protocols for the treatment of acute lymphoid leukemia of children: Distinction of two groups of patients according to predictable prognosis. Med. Pediatr. Oncol., 1978, 4: 17-27.

70. G. MATHE, J.L. MISSET, F. DE VASSAL, J. GOUVEIA, M. HAYAT, D. MACHOVER, D. BELPOMME , J.L. PICO, L. SCHWARZENBERG, P. RIBAUD, et al. Leukaemias and lymphomas treatment by vindesine. Result of a phase II trial in terms of remission induction. Nouv. Presse Med., 1978, 7(7): 525-528.

71. D. BELPOMME , A. BOHU, M. MUSSET, E. CARCIA-GIRALT et al. Controlled ECR 1 and ECR 2 trials of chemotherapy and chemo-immunotherapy in advanced gastric and colorectal carcinoma: Value of a cyclic sequential combination using VM 26, 5-Fluoro-uracil, Mitomycin-C, CCNU, and BCG. Eur. J. Cancer, 1978, 1 (suppl 1): 189-196.

72. D. BELPOMME , L. BORELLA, R. BRAYLAN, M. GREAVES, R. HERBERMAN, W. HITZIG, J. KERSEY, R. PETROV, E. RITTS, M. SELIGMANN, L. SOBIN, S. THIERFELDER, G. TORRIGIANI. Immunological diagnosis of leukemia and lymphoma: A World Health Organization/International Union of Immunological Societies Technical Report. Brit. J. Hematology, 1978, 38: 85-98.

73. G. MATHE, B. SERROU, M. HAYAT, F. DE VASSAL, J.L. MISSET, L. SCHWARZENBERG, D. MACHOVER, P. RIBAUD, D. BELPOMME , C. JASMIN, et al. Preliminary results of phase I and II clinical trials of RFCNU, a new nitrosourea sugar derivative, in digestive tract tumors. Biomedicine, 1977, 27: 294-297.

74. G. MATHE, F. DE VASSAL, L. SCHWARZENBERG, M. DELGADO, R. WEINER, M.A. GIL, J. PENA-ANGULO, D. BELPOMME , P. POUILLART, D. MACHOVER, et al. Résultat de trois protocoles de traitement de la leucémie aiguë lymphoïde des enfants. Arch. Franç. Péd., 1977, 34: 611-621.

75. A. SANTORO, D. BELPOMME , G. MATHE. T and B spleen lymphocytes in Hodgkin’s disease. Hematologica, 1977, 62: 11-22.

76. A.SANTORO, B. CAILLOU, D. BELPOMME . T and B lymphocytes and monocytes in the spleen in Hodgkin’s disease: The increase in T lymphocytes in involved spleens. Eur. J. Cancer, 1977, 13: 355-359.

77. M.C. SIMMLER, M. BRULEY-ROSSET, D. BELPOMME , L. SCHWARZENBERG. Clinical trial of Poly I - Poly C as an immunity adjuvant and an immunorestoration agent. Eur. J. Cancer, 1977, 13: 441-444.

78. R.R. JOSEPH, N. LELARGE, D. BELPOMME . Are circulating null cells in patients submitted to long-term immunotherapy, related to K cells ? Eur. J. Cancer, 1977, 13: 441-444.

79. D. DANTCHEV, D. BELPOMME . Critical study of the mononuclear leukocyte morphology based on scanning electron microscopy in normal subjects and in patients with lymphoïd or monocytoïd proliferative disorders. Comparison with the T, B or null cell membrane phenotypes. Biomedicine, 1977, 26: 202-222.

80. D. BELPOMME , N. LELARGE, R. JOSEPH, G. MATHE. An immunological classification of leukemias and non Hodgkin’s hematosarcomas based on T and B membrane markers with special reference to “null” cell disorders. Eur. J. Cancer, 1977, 13: 311-319.

81. GUIBOUT, J.F. DORE, L. MARHOLEV, C. ROSENFELD, D. BELPOMME . Définition sérologique d’un antigène associé aux leucémies aiguës lymphoblastiques. C.R. Acad. Sc., 1977, 285 D: 615.

82. D. BELPOMME , G. MATHE, A.J.S. DAVIES. Clinicial significance and prognostic of the T-B immunological classification of human primary acute lymphoid leukemias. Lancet, 1977, 1: 555-558.

83. G. MATHE, F. DE VASSAL, M. DELGADO, P. POUILLART, D. BELPOMME , R. JOSEPH, L. SCHWARZENBERG, J.L. AMIEL, M. SCHNEIDER, A. CATTAN, M. MUSSET, J.L. MISSET, C. JASMIN. 1975 current results of the first 100 cytologically typed acute lymphoid leukaemia submitted to BCG active immunotherapy. Cancer Immunol. Immunoth., 1976, 1: 77-86.

10

84. G. MATHE, P. POUILLART, F. DE VASSAL, M. DELGADO, L. SCHWARZENBERG, J.L. MISSET, M. HAYAT, C. JASMIN, D. BELPOMME , M. MUSSET. Haute fréquence des rémissions dans la leucémie aiguë myéloide (LAM) par la combinaison d’Adriamycine, de Vincristine et de Cytosine Arabinoside. Nouv. Presse Med., 1976, 5: 1758-1759.

85. G. MATHE, P. POUILLART, F. DE VASSAL, M. DELGADO, L. SCHWARZENBERG, J.L. MISSET, M. HAYAT, C. JASMIN, D. BELPOMME et M. MUSSET. Remission induction in acute lymphoid and acute myeloid leukeamias. Lancet, 1976, 1: 1130-1131.

86. G. MATHE, P. POUILLART, F. DE VASSAL, M. DELGADO, L. SCHWARZENBERG, J.L. MISSET, M. HAYAT, C. JASMIN, D. BELPOMME , M. MUSSET. Leucémie aiguë lymphoïde : induction constante de rémission par la combinaison de Prednisone, Vincristine et L-asparaginase. Nouv. Presse Méd., 1976, 5: 1491.

87. P. POUILLART, L. SCHWARZENBRG, T. PALANGIE, D. BELPOMME , G. MATHE, P. HUGUENIN, P. MORIN, H. GAUTIER, CH. LAGARDE, A. BARON. Associations chimiothérapiques dans le traitement des cancers du sein polymétastasés. Comparaison de l’effet thérapeutique de deux protocoles d’administration séquentielle des drogues. Rôle de l’Adriamycine dans ces combinaisons. Nouv. Presse Méd., 1976, 5: 2145-2150.

88. D. DANTCHEV, D. BELPOMME . Etude critique de la sémiologie morphologique des leucocytes mononuclées normaux et pathologiques à l’aide de la microscopie électronique à balayage. Rencontre biologique 1976. Exp. Scient. Franç., 1976, p. 13-36.

89. G. MATHE, D. BELPOMME , D. DANTCHEV. Les hématosarcomes non Hodgkiniens (Classification du Centre de Référence de l’O.M.S.). Ann. Anat. Pathol., 1976, 21(3): 285-300.

90. R.R. JOSEPH, D. BELPOMME , G. MATHE. Increase in "null" cells in acute lymphocytic leukaemia in remission long-term immunotherapy. Brit. J. Cancer, 1976, 33: 567-570.

91. D. BELPOMME , R. JOSEPH, N. LELARGE. Increase of null cells in patients submitted to long-term active immunotherapy. Cancer Immunol. Immunoth., 1976, 1: 113-114.

92. J.L. MISSET, P. POUILLART, J.L. AMIEL, L. SCHWARZENBERG, M. HAYAT, F. DE VASSAL, M. MUSSET, D. BELPOMME , C. JASMIN, C. ALBAHARY, R. DEPIERRE, G. MATHE. Combinaison d’Adriamycine, de VM26, de Cyclophosphamide et de Prednisone (AVmCP) pour la chimiothérapie des lymphoréticulosarcomes disséminés (stades ou formes topographiques III et IV). Nouv. Presse Méd., 1975, 4: 3117-3120.

93. G. MATHE, D. BELPOMME , P. POUILLART, L. SCHWARZENBERG, J.L. MISSET, M. SCHNEIDER. Preliminary results of an immunotherapy trial on terminal leukaemic lymphosarcoma. Biomedicine, 1975, 23: 465-467.

94. G. MATHE, D. BELPOMME , D. DANTCHEV, P. POUILLART, G. HAUSS, J.R. SCHLUMBERGER, M. LAFLEUR. Search for correlations between cytological types and therapeutic sensitivity of accute leukaemias. Blood Cells, 1975, 1: 37-52.

95. G. MATHE, D. BELPOMME , D. DANTCHEV, P. POUILLART, J.R. SCHLUMBERGER, M. LAFLEUR. Leukaemic lymphosarcomas: Respective prognosis of the three types: prolymphocytic, lymphoblastic (or lymphoblastoïd) and immunoblastic. Blood Cells, 1975, 1: 25-36.

96. G. MATHE, D. BELPOMME , D. DANTCHEV, A. KHALIL, A.M. AFIFI, N. TALEB, P. POUILLART, L. SCHWARZENBERG, M. HAYAT, F. DE VASSAL, C. JASMIN, J.L. MISSET, M. MUSSET. Immunoblastic lymphosarcoma. A cytological entity ? Biomedicine, 1975, 22: 473-488.

97. FLORENTIN, M. BRULEY, D. BELPOMME . Production of migration inhibition factor (MIF) by human established B type cell derived from normal and malignant tissues; studies of some factors affecting MIF release. Cell. Immunol., 1975, 17: 285-294.

98. R.R. JOSEPH and D. BELPOMME . T and B lymphocytes in spleen in Hodgkin’s disease. Lancet, 1975, 1: 747-748.

99. P. POUILLART, L. SCHWARZENBERG, D. BELPOMME , F. DE VASSAL, M. HAYAT, J.L. AMIEL, G. MATHE. La prévention des méningites leucémiques. Bull. Cancer, 1974, 61: 403-410.

100. G. MATHE, J.L. AMIEL, P. POUILLART, L. SCHWARZENBERG, M. HAYAT, F. DE VASSAL, D. BELPOMME , M. LAFLEUR. L’espérance de guérison des enfants atteints de leucémie aiguë lymphoide. Les facteurs du pronosticau début de la maladie. Arch. Franç. Pédiatr., 1974, 31: 271-283.

101. G. MATHE, P. POUILLART, J.L. AMIEL, L. SCHWARZENBERG, D. BELPOMME , M. HAYAT, M. SCHNEIDER, A. CATTAN, J.L. MISSET. Une classification cytologique de 100 cas de leucémies aiguës lymphoïdes : facteur du pronostic après immunothérapie. Bull. Cancer, 1974, 61: 309-320.

102. G. MATHE, J.L. AMIEL, L. SCHWARZENBERG, P. POUILLART, D. BELPOMME , M. HAYAT, M. SCHNEIDER, A. CATTAN, C. JASMIN, J.L. MISSET, et al. Dix ans d’immunothérapie des leucémies aiguës lymphoïdes : les facteurs pronostic autres que cytologiques. Bull. Cancer, 1974, 61: 377-386.

11

103. G. MATHE, D. BELPOMME . T and B lymphocytic nature of leukemias and lymphosarcomas: A new but still uncertain parameter of their classification. Biomedicine, 1974, 20: 81-85.

104. G. MATHE, D. BELPOMME , D. DANTCHEV, P. POUILLART, C. JASMIN, J.L. MISSET, M. MUSSET, J.L. AMIEL, J.R. SCHLUMBERGER, L. SCHWARZENBERG, et al. Immunoblastic acute lymphoid leukaemia. Biomedicine, 1974, 20: 333-340.

105. D. BELPOMME , D. DANTCHEV, F. DU RUSQUEC, D. GRANDJON, R. HUCHET, F. PINON, P. POUILLART, L. SCHWARZENBERG, J.L. AMIEL, G. MATHE. La nature T ou B des cellules néoplasiques des leucémies aiguës lymphoides. Bull. Cancer, 1974, 61: 387.

106. D. BELPOMME , D. DANTCHEV, F. DU RUSQUEC, D. GRANDJON, R. HUCHET, P. POUILLART, L. SCHWARZENBERG, J.L. AMIEL, G. MATHE. T and B lymphocyte markers on the neoplastic cells of 20 patients with acute and 10 patients with chronic lymphoid leukemia. Biomedicine, 1974, 20: 109-118.

107. D. BELPOMME , R. JOSEPH, L. NEVARES, R. GERARD-MARCHANT, R. HUCHET, I. BOTTO, D. GRANDJON, G. MATHE. T lymphocytes and reed-Sternberg cells in spleen of Hodgkin’s disease. New Engl. J. Med., 1974, 291: 1417.

108. R. LEVY, J. VALLIN, B. CALLET, J. COULBIN, P. DUPUY, D. BELPOMME , A. BERGUE, G. MOLAS, R. DUPUY, C. BETOURNE. Utilisation de la globuline antilymphocyte dans le traitement des hépatites chroniques actives. Concours Médical, 1973, 95-38: 5123-5146.

109. C. JACQUILLAT, D. BELPOMME , M. WEIL, G. AUCLERC, F. TEILLET, C. WEISGERGER, J. TANZER, M. BOIRON, J. BERNARD. Les néoplasies simultanées et successives : à propos de 18 observations d’affections malignes compliquant l’évolution de la maladie de Hodgkin. Nouv. Presse Méd., 1973, 2: 3089.

110. G. MATHE, L. SCHWARZENBERG, J.L. AMIEL, M. SCHNEIDER, D. BELPOMME , C. JASMIN, C. ROSENFELD, M. HAYAT, F. DE VASSAL, M. STERESCO. Bone marrow transplantation after antilymphocytes globulin condition split lymphocyte chimerism. Transplant. Proc., 1972, 4: 551-557.

111. L. SCHWARZENBERG, G. MATHE, J.L. AMIEL, M. SCHNEIDER, D. BELPOMME , J. CHOAY, P. TROLARD, C. JASMIN, C. ROSENFELD, M. HAYAT, F. DE VASSAL, M. STERESCO. Marrow transplantation in aplastic states employing antilymphocyte globulin (A.LG). Absence of secondary disease Split Lymphocyte chimerism. Exp. Hematol., 1972, 22: 109-117.

112. D. BELPOMME , P. BLONDEL, D. GRANDJON. La durée de vie des cultures de sang leucémiques humains. C.R. Acad. Sci., Paris, 1972, 274: 3480.

113. D. BELPOMME , J. MINOWADA, G.E. MOORE. Are some human lymphoblastoid cell lines established from leukeamic tissues actually derived from normal leucocytes ? Cancer, 1972, 30: 282.

114. D. BELPOMME , K. KUMAGAI, J. MINODAWA, G.E. MOORE. Human blood culture: cytological observations during the establishment of a permanent lymphoblastoid cell line. J. Med., 1971, 2: 363.

115. C. LEBORGNE DE KAOUEL, D. BELPOMME , J.F. DORE, C. AUBERT, D. GRANDJON. Obtention et entretien de lignée cellulaires permanentes établies à partir de malades leucémiques. Rev. Fr. et Clin. Biol., 1969, 14: 530.

116. D. BELPOMME , C. LEBORGNE DE KAOUEL, M. PAINTRAND, A.M. VENUAT, C. DE NAVA, D. GRANDJON, C. THOYER, J. DE GROUCHY, G. DE THE, G. MATHE. Aspects morphologiques de plusieurs lignées permanentes ICIG établies à partir de sang leucémique humain. Rev. Fr. et Clin. Biol., 1969, 14: 848.

117. D. BELPOMME , C. LEBORGNE DE KAOUEL, E. AJURIA, C. JASMIN, J.F. DORE. Increase in antigenicity of permanent tissue culture line ICIG 101. Nature, 1969, 222: 890.

118. D. BELPOMME , G. SEMAN, J.F. DORE, A.M. VENUAT, L. BERUMEN, G. MATHE. Established cell line ICIG 101 obtained from frozen human lymphobastoid leukemia cells: Morphological and immunological comparison with the patient’s fresh cells. Eur. J. Cancer, 1969, 5: 55.

DIDACTIC ARTICLES 119. D. BELPOMME . Cancer, le poids de l’environnement. La science au présent, Encyclopedia Universalis,

2005. 120. D. BELPOMME . Editorial. Oncology, 2004, 6: 227-228. 121. D. BELPOMME . Mission interministérielle pour la lutte contre le cancer : "Rôle de l’environnement

dans la genèse des cancers, conséquences pour l’organisation des structures de surveillance et des coordinations des recherches du futur Institut National du Cancer et mesures de précaution et de prévention", 2002.

122. D. BELPOMME . Impact of cytotoxic treatments in oncology. Djeddah, 2003.

12

123. D. BELPOMME . The latest breakthroughs in anticancer medical treatment. A genuine role for non cytotoxic drugs. Djeddah, 2003.

124. D. BELPOMME . L’essor des chimiothérapies non cytotoxiques. Thérapeutique et Pratique Hospitalière (T.P.H.), 2001, 12(59): 8-12.

125. D. BELPOMME . Cancer et alimentation. Sciences, 2001, 3: 1-18. 126. D. BELPOMME . Nouvelles molécules anticancéreuses. Cancérologie Aujourd’hui, 1997. 127. D. BELPOMME , R. GUILLOT. Cancer : Mythes, Réalité, Espoir. Sciences, 1997, 9-36. 128. D. BELPOMME . Une remise en question du modèle de Goldie-Coldman. Lettre du Cancérologue, 1997,

6: 5-8. 129. D. BELPOMME . Chimiothérapie anticancéreuse : les nouveaux médicaments. Thérapeutique et Pratique

Hospitalière (T.P.H.), 1996, 42: 3-4. 130. D. BELPOMME . L’essor des nouveaux médicaments anticancéreux. Cancérologie Aujourd’hui, 1996, 4

(5): 186-190. 131. D. BELPOMME . Nouvelles molécules anticancéreuses : l’état actuel des recherches. Cancérologie

Aujourd’hui, 1994, Special Issue: 3-13. 132. F.N. MARIE, N. FRETAULT, D. BELPOMME . Le cancer devenu première cause de mortalité.

Cancérologie Aujourd’hui, 1993, 2: 187-189. 133. D. BELPOMME . Cancers de l’ovaire : de la chimiothérapie classique aux thérapies géniques. Lettre du

Cancérologue, 1993. 134. D. BELPOMME , M. LE BONNIEC. Nouvelles molécules anti-cancéreuses : l’état actuel des recherches.

Cancérologie Aujourd’hui, 1992, Special Issue: 3-8. 135. M.C. PINEL, G. PINON, M.J. GOUDIER, B. COIFFIER, M.H. FILIPPI, A. GOUPIL, B. ROULLET, T.

FACCHINI, L. MIGNOT, P. TRESCA, M. DELGADO, D. BELPOMME . Etude de l’association Vinorelbine-Hexamethylmelamine (V-H) dans les adénocarcinomes ovariens évolués : résultats préliminaires de l’essai de phase I-II, NHO-88, du groupe "ovaire" de l’ARTAC. In "Navelbine : actualités et perspectives", Ed. P.F. Médicament, Paris, 1990.

136. D. BELPOMME , M.C. PINEL, B. LASSALE. Les ostéosarcomes ostéogéniques II. Le traitement. Concours médical, 1990, 112: 335-342.

137. D. BELPOMME , M.C. PINEL, B. LASSALE. Les ostéosarcomes ostéogéniques I. Le diagnostic. Concours médical, 1990, 112: 245-247.

138. D. BELPOMME , P. TRESCA. Chimiothérapie anticancéreuse : nouveaux médicaments, nouveaux concepts. Méd. Chir. Dig., 1990, 19: 273-281.

139. D. BELPOMME , M.C. PINEL, P. TRESCA. Adénocarcinomes de l’ovaire : acquisitions thérapeutiques récentes. Tempo médical, 1989, 363A: 9-12.

140. D. BELPOMME , F.N. MARIE, M.C. PINEL, P. SCHNEIDER, F. HERITIER, J.M. MONDESIR. La conception et la gestion des essais cliniques en cancérologie : pourquoi et comment l’ARTAC. Cancer Communication, 1988, 2: 295-308.

141. D. BELPOMME . L’expérimentation thérapeutique en cancérologie : état actuel et perspectives. Cancer Communication, 1988, 2: 241-244.

142. D. BELPOMME . Acquisitions récentes dans le traitement des adénocarcinomes de l’ovaire : le pronostic, la place des traitements locorégionaux, les nouveaux médicaments et nouvelles stratégies, la chimio-radiothérapie lourde suivie d’autogreffe de moëlle osseuse. In "Actualités Gynécologiques", Ed. A. Netter, Masson, 1987, p.9-23.

143. D. BELPOMME , L. MIGNOT, M. BOIRON. Cancers du sein. In "Traité de médecine de P. Godeau", Ed. Flammarion, 1987, Chap. 26, p.34-63.

144. B. DAUTZENBERG, B. ANDREASSIAN, R. ARRIAGADA, D. BELPOMME , and the GETCB. Les traitements des cancers bronchiques. Colloque CNAM-INSERM, 1986.

145. D. BELPOMME . Les perspectives nouvelles de traitement des adénocarcinomes ovariens. Lettre Roger Bellon, 1986, N°50.

146. D. BELPOMME , G. BENHAMOU. Place de la chimiothérapie et de l’immunothérapie dans le traitement des cancers digestifs. Entretiens Bichat, Table ronde, 1985.

147. C. GISSELBRECHT, D. BELPOMME , M. ESPIE, L. MIGNOT, M. MARTY, M. BOIRON. La chimiothérapie dans les traitements des cancers de l’estomac et du pancréas. In "Actualités cancérologique, Institut Gustave Roussy", Ed. Masson, Paris, 1985, p.165-175.

148. C. GISSELBRECHT, L. MIGNOT, D. BELPOMME , M. MARTY. Classification, mode d’action et place de la chimiothérapie, de l’hormonothérapie et de l’immunothérapie. Encyclopédie Médico-chirurgicale, 1983, 10: 1-28.

13

149. D. BELPOMME , H. GAUTIER, M. MARTY. Progrès de la chimiothérapie dans les cancers bronchiques primitifs non anaplasiques à petites cellules : apport des combinaisons basées sur le Cis-Platinum. Lettre Roger Bellon, 1982, N°10.

150. D. BELPOMME , C. GISSELBRECHT, M. MARTY, L. MIGNOT, M. BOIRON. Chimiothérapie des cancers du tube digestif. Encyclopédie Médico-chirurgicale, 1982, 9120 A10, 6: 1-10.

151. D. BELPOMME , L. MIGNOT. L’hypothermie du cuir chevelu : un moyen efficace pour prévenir l’alopécie des chimiothérapies anticancéreuses. Lettre Roger Bellon, 1981, N°1.

152. D. BELPOMME , M. MARTY, C. GISSELBRECHT. L’immunothérapie des cancers. Sem. Hôp. Paris, 1981, 57: 1547-1556.

153. C. BERSAY, P. BENOIT, D. BELPOMME , J.P. COQUILLAUD, P. MARLAND. La certitude du diagnostic. Poumon - Coeur, 1981, 37: 155.

154. D. BELPOMME , L. MIGNOT, M. BOIRON. Cancers du sein. In "Traité de Médecine" de P. Godeau, Ed. Flammarion, Paris, 1981, Chap. 21, p.1823-1838.

155. D. BELPOMME , A. ELIAS, G. GION, E. PUJADE-LAURAINE, L. MIGNOT, C. GISSELBRECHT, M. MARTY, P. JAULIN, M. BOIRON. Dosage de l’antigène carciono-embryonnaire (ACE) selon 2 méthodes différentes : application aux tumeurs digestives et gynécologiques. Méd. Prat., 1981, 5: 105-110

156. T. MONTARIOL, P. CABANIS, D. BELPOMME , J. ROGE. Cancer de l’estomac. Encycl. Méd. Chir., Paris, Thérapeutique, 25526 A-10, 180, 5: 1-14.

157. LEROL, A. BOHU, C. BERSAY, D. BELPOMME . Le rôle du généraliste dans le dépistage du cancer. Méd. Prat., 1980, 2: 41-49.

158. D. BELPOMME . Epidémiologie des cancers : intérêt pour leur prévention et détection. Gaz. Méd. de France, 1980, 87: 1723-1734.

159. D. BELPOMME . Croissance tumorale et histoire naturelle des cancers. Gaz. Méd. de France, 1980, 87: 1597-1608.

160. D. BELPOMME , L. MIGNOT, C. GISSELBRECHT, E. PUJADE-LAURAINE, M. MARTY, M. BOIRON. Chimiothérapie des cancers de l’ovaire : progrès actuels et perspectives nouvelles. Entretiens de Bichat. Thérapeutique, 1980, pp. 109-114.

161. M. MARTY, C. GISSELBRECHT, D. BELPOMME . Théorie moléculaire du cancer. Méd. Prat., 1980, 4: 47-51.

162. D. BELPOMME . Cancers de la pollution environnementale et de l’alimentation. Méd. Prat., 1979, 6: 65-69.

163. D. BELPOMME , M. MARTY. Peut-on redéfinir le cancer en 1979 ? Méd. Prat., 1979, 5: 83-96. 164. D. BELPOMME . Vers un renouveau de la cancérologie. Méd. Prat., 1979, 4: 9-10. 165. D. BELPOMME , E. PUJADE-LAURAINE. Facteurs de pronostic et traitement du myélome multiple.

Entretiens de Bichat. Actualités Cancérologiques 1979 à l’usage du praticien. Exp. Scient. Franç., 1979, pp. 73-80.

166. D. BELPOMME , A. BOHU, C. GISSELBRECHT, M. MARTY. Nécessité d’essais coopérateurs contrôlés de chimiothérapie et d’immunothérapie pour le traitement des tumeurs digestives. Entretiens de Bichat. Actualités Cancérologiques 1979 à l’usage du praticien. Exp. Scient. Franç., 1979, pp. 31-41.

167. A.J.S. DAVIES, D. BELPOMME . Introductory remarks. In "Human lymphocyte differentiation: its application to cancer", INSERM Symposium n°8 (B. Serrou and C. Rosenfeld), Ed. Elsevier/North-Holland Biomedical Press, 1978, p.215-220.

168. D. BELPOMME , D. IRONDELLE, E. PUJADE-LAURAINE, A. BOHU, M. MUSSET, A. LEROL, M. LEVARDON, J. SENEZE. Apports de la chimiothérapie et de l’immunothérapie dans le traitement des tumeurs gynécologiques. Rev. Franç. Gynéc., 1978, 73: 589-597.

169. D. BELPOMME , N. LELARGE, G. MATHE, A.J.S. DAVIES. Etiological Clinical and Prognostic significance of the T-B immunological classification of primary acute lymphoid leukemias and non Hodgkin’s lymphomas. In "Immunological diagnosis of leukemias and lymphomas", Vol. 20 (S. Thierfelder, H. Rodt, E. Thiel eds.), Ed. Springer Verlag, Heildelberg, 1977, pp. 33-45.

170. D. BELPOMME , A. BOHU, M. MUSSET. Chimiothérapie et immunothérapie post-opératoires des cancers de l’estomac et du côlon-rectum. Entretiens de Bichat. Cancérologie, 1977, pp. 33-41.

171. D. BELPOMME . Lymphoréticulosarcomes : de l’inventaire aux indications thérapeutiques. Entretiens de Bichat. Cancérologie, 1977, pp. 103-114.

172. D. BELPOMME , G. MATHE. Valeur pronostique des deux paramètres cytologique et immunologique de classification des leucémies aiguës lymphoïdes et des lympho-réticulosarcomes. Rencontre Biologique 1977. Exp. Scient. Franç., 1977, pp. 10-14.

173. G. MATHE, D. BELPOMME . Les leucémies et lymphosarcomes à immunoblastes. Entretiens de Bichat. Le Praticien face aux problèmes du cancer. Exp. Scient. Franç., 1976, pp. 131-134.

14

174. G. MATHE, D. BELPOMME , D. DANTCHEV, P. POUILLART. Les récents progrès réalisés dans la classification des leucémies lymphoïdes et monocytoïdes et des lymphos et réticulosarcomes. Pharmacien Biologiste, 1976, 19: 213-222.

175. G. MATHE, D. BELPOMME , D. DANTCHEV. Les leucémies et lymphosarcomes immunoblastiques. Rencontre Biologique 1976. Exp. Scient. Franç., 1976, pp. 9-12.

176. D. BELPOMME , R. JOSEPH, F. FEUILHADE DE CHAUVIN, G. MATHE. L’aide du biologiste médical au clinicien en présence des pluricytopénies en apparence idiopathique. Vie Méd., 1976, 57: 2277-2282.

177. G. MATHE, D. BELPOMME , D. DANTCHEV, P. POUILLART. Les récents progrès réalisés dans la classification des leucémies lymphoïdes et monocytoïdes et des lymphos et réticulosarcomes. Ann. Méd. Interne, 1975, 216: 523-534.

178. G. MATHE, D. BELPOMME , D. DANTCHEV, P. POUILLART. Progress in the classification of lymphoïd and/or monocytoïd leukemia. Biomedicine, 1975, 22: 177-185.

179. D. BELPOMME , D. PONVERT, G. MATHE. Une nouvelle méthode d’exploration des lymphocytes et monocytes par leurs marqueurs de membrane : son intérêt en pathologie. Rencontre Biologique 1975. Exp. Scient. Franç., 1975, pp. 25-29.

180. D. BELPOMME , H. RAPPAPORT, G. MATHE. Histopathologie et histogénèse de la maladie de Hodgkin. Rev. Prat., 1974, 24: 3911-3923.

181. G. MATHE, J. BREARD, M.C. SIMMLER, D. BELPOMME , R. WEINER, R. OLDHAM. L’exploration immunitaire des malades cancéreux. Entretiens de Bichat. Exp. Scient. Franç., 1974, pp. 121-123.

182. D. BELPOMME , P. BLONDEL, G. MATHE. Les cancers d’origine thérapeutique. Compte-rendu du Congrès Français de Médecine (Beyrouth), 1972, pp. 283-304.

183. D. BELPOMME , P. BLONDEL, G. MATHE. Les cancers d’origine thérapeutique. Vie méd. au Canada, 1972, 1: 140-150.

15

CONGRESS AND SYMPOSIUM CONTRIBUTION IN CONGRESS AND SYMPOSIUM • "Prévention des risques chimiques et sécurité au travail dans les métiers de la restauration et de

l’hôtellerie", 1 October 2009, GECO, Issy-les-Moulineaux. • Colloquium "Ila giornata in ricordo di Lorenzo TOMATIS", 22 September 2009, ISDE Italian, Bologna. • "Alimentation et Santé", 26 May 2009, University of Geneva, Geneva, Switzerland. • "Santé des femmes et environnement", 23 February 2008, Woman Institute of Monaco (WIM) and the

Medical Imagery Center of Monaco (CIMM), United Nations for Environment Program, Monaco, Monaco.

• "Which life on an impoverished planet", 21 January 2008, University Faculties Notre-Dame de la Paix, Namur.

• "2ème journée internationale de recherche inter-caraïbe en cancérologie", 7-9 December 2007, AMREC, Sainte-Luce, Martinique.

• 12th World Congress on Advances in Oncology and 10th International Symposium on Molecular Medicine, 11-13 October 2007, Medical School University of Crete, International Journal of Oncology, Oncology Reports, International Journal of Molecular Medicine and Molecular Medicine Reports, Creta Maris, Hersonissos, Crete.

• Gynovations, "L’environnement et les maladies des femmes", 9 June 2007, Monaco, Monaco. • "Conférence de Paris pour une gouvernance mondiale : combattre les pollutions et préserver la santé", 2-3

February 2007, Paris. • 2nd International Colloquium of the Paris Appeal, "Environnement et santé durable : une expertise

internationale", 9 November 2006, UNESCO, Paris. • European Press Conference in partenership with the Standard Comitee of european Doctors (Medical

board of 25 EU Members States) on the project of the REACH Regulation (regulation on chemicals), 18 October 2006, European Parliament, Brussels.

• "Santé-Environnement", 27 April 2006, Collège des Hautes Études de l’Environnement & du Développement Durable, Paris.

• European Press Conference in partenership with the Permanent Comitee of Doctors on the project of the REACH Regulation, "L'Appel de Paris : pour un REACH fort", 8 November 2005, European Parliament, Brussels.

• 15th Stockholm Water Symposium, 23-24 August 2005, Stockholm International Water Institute, Stockholm.

• Eurocancer, "Dépistage et prévention", 23 June 2005, Paris. • European Colloquium "Environment and Health", 13 June 2005, Luxembourg Health Ministry,

Luxembourg. • "L’Europe : une chance pour l’écologie ?", 11 May 2005, Ministry of Ecology and Sustainable

Development, Paris. • Audience at the Royal Medicine Academy office of Belgium, 19 March 2005, Brussels. • "Chimie et société", 8 December 2004, French Society of Chemistry, Paris. • 4th WHO Interministrial Conference (World Health Organisation) on Environment and Health, "A Future

for our Children", 23-28 June 2004, Budapest. • "La part des facteurs environnementaux dans la genèse des cancers", 1 June 2004, Academy of

Sciences, Paris. • 1st International Colloquium of the Paris Appeal, "Cancer, environment and society", 7 May 2004,

UNESCO, Paris. • Colloquium "Dépistage et prise en charge des cancers : l'importance de l'imagerie médicale", 31 January

2004, St Amand-Montrond. • Cancer 2002 : An International Symposium, "Development of non cytotoxic cancer chemotherapy", 14-16

October 2002, King Faisal Specialist Hospital and Research Centre, Riyadh, Kingdom of Saudi Arabia. • 23rd Congress of the European Society of Medical Oncology (ESMO), 6-10 November 1998, Athens. • 1998 Annual Meeting of the American Society of Clinical Oncology (ASCO), May 1998, Los Angeles,

USA. • 8th SOMPS, 3-6 February 1998, Paris. • 5th Franco-Japenese Meeting, September 1997, Institut Gustave Roussy, Villejuif. • Colloquium Medico-Pharmaceutical French-Turkish, May 1997, Ankara-Istanbul, Turquie.

16

• "17ème Forum de Cancérolgie", May 1997, Paris. • 1997 Annual Meeting of the American Society of Clinical Oncology (ASCO), May 1997, Denver, USA. • 88th Annual Meeting of the American Association for Cancer Research (AACR), April 1997, San Diego,

USA. • 114th Congress of the "Association Française pour l'Avancement des Sciences" (AFAS), November 1996,

Paris. • 1996 Annual Meeting of the American Society of Clinical Oncology (ASCO), May 1996, Philadelphia,

USA. • 87th Annual Meeting of the American Association for Cancer Research (AACR), April 1996, Washington,

USA. • 8th European Conference on Clinical Oncology and Cancer (ECCO8), 29 October - 2 November 1995, Paris. • Genetic engineering and gene therapy ARS Medical Congress, 20-21 October 1995, Brussels. • 1995 Annual Meeting of the American Society of Clinical Oncology (ASCO), 20-23 May 1995, Los

Angeles, USA. • 86th Annual Meeting of the American Association for Cancer Research (AACR), 18-22 March 1995,

Toronto, Canada. • 26th Annual Meeting of the Society of Gynecologic Oncologists (SGO), 19-22 February 1995, San

Francisco, USA. • 5th SOMPS, 31 January - 3 February 1995, Paris. • 19th Congress of the European Society of Medical Oncology (ESMO), 8-22 November, 1994, Lisbonne. • 1st International Conference on ReversaI of Multidrug Resistance in Cancer, 1-3 September 1994, St Gallen,

Switzerland. • Private meeting of ARTAC investigators, 1 June 1994, Maison de la Recherche, Paris. • 1994 Annual Meeting of the American Society of Clinical Oncology (ASCO), 14-17 May 1994, Dallas,

USA. • 1st Euroconference on Apoptosis, 19-20 September 1993, European School of Haematology, Paris. • European School of Oncology, 6-9 September 1993, Sophia Antipolis, Antibes. • INSERM, Unité 29, 2 July 1993, Paris. • "Early Development of New Anticancer Drugs in France and in Japan" organized by J.P. Armand, July 1993,

Paris. • Consensus workshop on Ovarian Carcinoma, 15-19 June 1993, Copenhagen. • 84th Annual Meeting of the American Association for Cancer Research (AACR), 19-22 May 1993, Orlando,

USA. • 1993 Annual Meeting of the American Society of Clinical Oncology (ASCO), 15-18 May 1993, Orlando,

USA. • "Club différenciation et apoptose" organized by L. Degos and L. Israel, 3 May 1993, ARC, Villejuif. • 83rd Annual Meeting of the American Association for Cancer Research (AACR), 20-23 May 1992, San Diego,

USA. • 1992 Annual Meeting of the American Society of Clinical Oncology (ASCO), 17-19 May 1992, San Diego, USA. • 6th European Conference on Clinical Oncology and Cancer Nursing (ECCO6), October 1991, Florence. • 4th International Workshop of the ARTAC on Therapeutic Trials in Cancer and AIDS, 25-27 September

1991, Paris. • 1991 Annual Meeting of the American Society of Clinical Oncology (ASCO), 19-21 May 1991, Houston,

USA. • 82nd Annual Meeting of the American Association for Cancer Research (AACR), 15-18 May 1991,

Houston, USA. • 3rd International Congress on Neo-adjuvant Chemotherapy, 6-9 February 1991, Paris. • 3rd National Congress of the "Société Française de Cancérologie privée", 18-19 January 1991, Paris. • 15th Congress of the European Society of Medical Oncology (ESMO), December 1990, Copenhagen. • "12ème Journée Nationale de la Sociéte Française de Sénologie et de Pathologie mammaire", November

1990, Paris. • 3rd Annual Congress on International consensus on Supportive Care in Oncology (ISCO), 1990, Brussels. • 15th International Cancer Congress of the "Union Internationale Contre le Cancer" (UICC), 1990, Hambourg. • 3rd Symposium of the "Société Francophone de Cancérologie", June 1990, Paris. • "10ème Forum de Cancérologie", June 1990, AFEC, Paris. • Symposium of the "Sociétés Française de Cancérologie privée et Belge de sénologie", May 1990, Brussels. • Meeting of the "Société Française de Gynécologie", May 1990, Paris. • 81st Annual Meeting of the American Association for Cancer Research (AACR), 1990, Washington, USA.

17

• 1990 Annual Meeting of the American Society of Clinical Oncology (ASCO), May 1990, Washington, USA.

• Seminary at the Upjohn Company, March 1990, Ka1amazoo, USA. • 2nd International Symposium on supportive care in cancer patients, February-March 1990, St Gallen, Switzerland. • 10th Congress Argentino del dolor, 1989, Buenos Aires, Argentina. • 5th Annual Meeting of the European Conference on Clinical Oncology (ECCO5), 1989, London. • Symposium P. F. Médicament "Navelbine", 1989, Biarritz. • "9ème Forum de Cancérologie", 1989, AFEC, Paris. • International Symposium of the EORTC Foundation, 1989, Paris. • 2nd International Symposium of the Israel Pain Association, 1989, Herzliya, Israel. • 3rd Workshop of the ARTAC on Therapeutic Trials in Oncology, "Scientific concepts, methodology and

new drugs", October 1989, Maison de la Chimie, Paris. • 80th Annual Meeting of the American Association for Cancer Research (AACR), May 1989, San Francisco, USA. • 1989 Annual Meeting of the American Society of Clinical Oncology (ASCO), May 1989, San Francisco,

USA. • 6th NCI-EORTC Symposium on New Drugs in Cancer Therapy, March 1989, Amsterdam. • 79th Annual Meeting of the American Association for Cancer Research (AACR), 1988, New Orleans,

USA. • 1988 Annual Meeting of the American Society of Clinical Oncology (ASCO), 1988, New Orleans, USA. • 13th Congress of the European Society of Medical Oncology (ESMO), 1988, Lungano, Switzerland. • 2nd International Congress on Neo-adjuvant Chemotherapy, February 1988, Paris. • "9ème Journée Nationale de la Société Française de Sénologie et de Pathologie mammaire", 1987,

Avignon. • Meeting of the "Société Française de Gynécologie", 1987, Paris. • Meeting of the "Société Française de Gynécologie", 1987, Paris. • Symposium of the "Société de Pneumologie de Langue Française", 1987, Marseille. • Symposium "Information et communication en cancérologie, outils et techniques", ONCOBA, 1987, Paris. • "8ème Forum de Cancérologie", 1987, AFEC, Paris. • Symposium Lederlé on the "Mitoxantrone", 1987, Madrid. • 4th Annual Meeting of the European Conference on Clinique Oncology (ECCO4), 1987, Madrid. • 6th International Meeting of Pharmaceutical Physicians, 1987, Brighton. • 1987 Annual Meeting of the American Society of Clinical Oncology (ASCO), 1987, Atlanta, USA. • Symposium "La prévention en 1987", April 1987, Paris. • 2nd Workshop of the ARTAC on "Expérimentation thérapeutique en cancérologie : les nouveaux médicaments et

nouvelles stratégies développées en France pour le traitement des cancers et du SIDA", 1987, Paris. • Entretiens de Bichat, 30 September 1987, Paris. • 4th Annual Meeting of the "Association Française d'Oncologie" (AFO), 1986, Cannes. • 1st Roche Symposium, "Le 5-Fluorouracile : nouveaux développements", 1986, Neuilly. • Symposium Lederlé, "Journée Française d'études sur la Mitoxantrone", 1986, Paris. • 4th Meeting of "Interféronistes de Langue Française", 1986, Annecy. • Congress of the "Société Européenne de Pneumologie", 1986, Paris. • 12th Annual Meeting of the European Society of Medical Oncology (ESMO), 1986, Nice. • 1986 Annual Meeting of American Society of Clinica1 Oncology (ASCO), 1986, Los Angeles, USA. • 1st Workshop of the ARTAC on "Good Clinical Practice et l'expérimentation thérapeutique en

cancérologie", May 1986, Villejuif. • "1ère journée de cancérologie de Charlebourg", 1985, Neuilly. • Symposium "La qualité de vie des cancéreux", 1985, AFEC, Paris. • French-Dutch Workshop on "Méthodes de préparation et les indications des interférons en cancérologie",

1985, Hôpital Bichat, Paris. • 13rd Annual Meeting of the International Society for Oncodevelopmental Biology and Medicine, 1985,

Paris. • 3rd Annual Meeting of the European Conference on Clinical Oncology (ECCO3), 1985, Stockhlom. • "Journée Française de Pneumologie", 1984, Nice. • Meeting of the "Société Française de Gynécologie", 1984, Paris. • "4ème Forum de cancérologie", 1984, AFEC, Paris. • 10th Annual Meeting of the European Society of Medical Oncology (ESMO), 1984, Nice. • "2ème Journée sur la Fertilité", 1983, Paris.

18

• European Congress "Les cancers avant, pendant, après", 1983, Ligue contre le cancer, Paris. • 1st Annual Meeting of the European Conference of Clinical Oncology (ECCO1), 1983, Amsterdam. • Colloquium "Chronothérapie et Pompes", 1982, Bordeaux. • "1ère Journée sur la Fertilité", 1982, Paris. • Symposium "Les cancers de l'ovaire", 1982, AFEC, Paris. • "2ème Forum de Cancérologie", 1982, AFEC, Paris. • 1982 Annual Meeting of the American Society of Clinical Oncology (ASCO), 1982, Seattle, USA. • 73rd Annual Meeting of the American Association for Cancer Research (AACR), 1982, Seattle, USA. • 7th Annual Meeting of the European Society of Medical Oncology (ESMO), 1981, Lausanne, Switzerland. • 1981 Annual Meeting of the American Society of Clinical Oncology (ASCO), 1981. • Entretiens de Bichat, 1980, Paris. • 6th Annual Meeting of the European Society of Medical Oncology (ESMO), 1980, Nice. • Symposium "Ruman lymphocytes differenciation: its application to cancer", 1979, INSERM, Montpellier. • "Semaine immunocancérologique", 1979, Paris. • 5th Annual Meeting of the European Society of Medical Oncology (ESMO), 1979, Nice. • Entretiens de Bichat, "Actualités cancérologiques", 1979, Paris. • "Semaine immunocancérologique", 1978, Paris. • 8th International Symposium on Comparative Research on Leukemia and Related Diseases, 1977, Amsterdam. • Rencontre biologique, "Journées biologiques et médicales", 1977, Paris. • Entretiens de Bichat, "Cancérologie", 1977, Paris. • 3rd French Congress of Haematology, 1977, Brussels. • 1st Symposium on Experimental Approaches to the Treatment of Gastrointestinal Tumors, 1977, Brussels. • "Enseignement national post-universitaire de gastroentérologie", 1977, Strasbourg. • 3rd Annual Meeting of the European Society of Medical Oncology (ESMO), 1977, Nice. • CNRS International Colloquium on "Néoplasies lymphoïdes", 1977, Paris. • "Société médicale des Hôpitaux de Paris", March 1977, Paris. • EORTC Symposium, "Clinical tumor immunology", 1976, Brussels. • International Symposium "Biological characterisation of human tumors", 1976, Amsterdam. • Workshop on the "Techniques de séparation et d'identification des lymphocytes humains", 1976,

INSERM, Montpellier. • Seminars within the framework of the French Mission in Egypt, December 1976, Cairo, Egypt. • International Symposium on recent trends in the immunological diagnosis of leukemias and lymphomas,

1976, Munich. • 2nd Congress of the "Société de Médecine Interne Cancérologique", December 1976, Nice. • "Semaine immunocancérologique de Paris", June 1976, Paris. • 1st Congress of the "Société de Médecine Interne Cancérologique", December 1975, Nice. • "Journées Biologiques et Médicales", October 1975, Cholet. • Roussel Uclaf Meeting, 1975, Paris. • 3rd Annual Meeting of the European Association for Cancer Research (EACR), September 1975,

Nottingham. • European Meeting of Immunology, September 1975, Amsterdam. • "Semaine immunocancérologique de Paris", June 1975, Paris. • EORTC Symposium, "Immunité Tumorale Humaine", May 1975, Brussels. • 66th Annual Meeting of the American Association For Cancer Research (AACR), 1975. • 6th Symposium on the Biological Characterization of Human Tumours, May 1975, Copenhagen. • International Course on Immunology, December 1974, Rio de Janeiro, Argentina. • Entretiens de Bichat, 1974, Paris. • 11th International Cancer Congress, October 1974, Florence. • Symposium on classification of unclassified leukemias, October 1974, Kremlin-Bicêtre. • International Symposium on Standardization in Haematology and Clinical Pathology, September 1974,

Foggia. • 15th International Congress of International Society of Haematology, September 1974, Jerusalem, Israel. • 3rd Annual Meeting of the International Society for Experimental Haematology, March 1974, Houston,

USA. • 65th Annual Meeting of the American Association for Cancer Research (AACR), 1974. • "Semaine Immunocancérologique", June 1973, Paris. • "Semaine Immunocancérologique", June 1972, Paris.

19

• 23rd French Congress of Medecine, 1971, Beyrouth, Liban. • 23th International Congress of Haematology, 1970, Munich. • International Congress of Genetics, 1969, Paris. SCIENTIFIC COMMUNICATIONS 1. D. BELPOMME . Le cancer une maladie de l’environnement. 2ème journée internationale de Recherche

Intercaraïbe en cancérologie, 7-9 December 2007, Sainte-Luce, Martinique. 2. D. BELPOMME . A reappraisal of the risk attributable to environmental carcinogens. 12th World

Congress on Advances in Oncology and 10th International Symposium on Molecular Medicine, 11-13 October 2007, Hersonissos, Crete.

3. D. BELPOMME . Le concept de santé durable et le Mémorandum de l’Appel de Paris. Colloque international de l’Appel de Paris Environnement et santé durable : une expertise internationale, 9 November 2006, UNESCO, Paris.

4. D. BELPOMME . Reinforce REACH: 2 million medical doctors call out to eurodeputes. Press Conference in the European Parliaement, 18 October 2006, Brussels.

5. D. BELPOMME . Substances chimiques et cancer : quelles preuves ? Santé – Environnement. Collège des Hautes Études de l’Environnement et du Développement Durable, 27 April 2006.

6. D. BELPOMME . Quelle alimentation pour demain ? Nourrir les hommes, nourrir le monde. Université de la Terre, Fondation Nature et Découverte, UNESCO, 19 November 2005, Paris.

7. D. BELPOMME . L’Appel de Paris, déclaration internationale sur les dangers sanitaires des polluants chimiques. Conférence de presse au Parlement Européen L’Appel de Paris : Pour un REACH fort, 8 November 2005, Brussels.

8. D. BELPOMME . Cancer and environmental factors: it is time to change our understanding of the disease. FAO, October 2005, Rome.

9. D. BELPOMME . Human diseases induced by chemical pollution: the Paris Appeal. 15th Stockholm Water Symposium, Stockholm International Water Institute, 23-24 August 2005, Stockholm.

10. D. BELPOMME . Inter-relation Environment and Health. Colloque européen au Ministère de la Santé du Luxembourg : Environment and Health, 13-15 June 2005, Luxembourg.

11. D. BELPOMME . Quelle est l’amplitude de la part de l’environnement dans la genèse des cancers et comment la mesurer ? Académie Royale de Médecine de Belgique, 19 March 2005, Brussels.

12. D. BELPOMME . La part de la pollution physico-chimique dans la genèse des cancers. Maison de la Chimie, December 2004, Paris.

13. D. BELPOMME . Santé et environnement : l’Appel de Paris. 4ème Conférence interministérielle de l’OMS (Organisation Mondiale de la Santé) sur l’environnement et la santé : un futur pour nos enfants, 23-28 June 2004, Budapest.

14. D. BELPOMME . Santé, environnement et société : une introduction. Sciences Po, 2 June 2004, Paris. 15. D. BELPOMME . La part de l’environnement dans la genèse des cancers. Académie des Sciences, 1 June

2004, Paris. 16. D. BELPOMME . Le cancer, maladie de l’environnement. Cancer, environnement et société, UNESCO,

May 2004, Paris. 17. D. BELPOMME . Dépistage et prise en charge des cancers. Colloque Saint Amand-Montrond, January 2004, St

Amand-Montrond. 18. D. BELPOMME . Special lecture on medical oncology. Princess Norah Cancer Center, June 2003,

Jeddah, Kingdom of Saudi Arabia. 19. D. BELPOMME . New Drugs in anti-cancer chemotherapy. November 1999, Irak and December 1999,

Iran. 20. W. TEN BOKKEL HUININK, R. PARIDAENS, M. PICCART, M.J. MILLWARD, J.M. NABHOLTZ,

C. LALANDE, A. LEBECQ, A. RIVA, C. GOUSSET, D. BELPOMME . Docetaxel (DOC) in heavily pretreated Metastatic Breast Cancer (MBC): analysis of an international compassionate-use trial. Proc. ASCO, May 1999, Atlanta, USA.

21. X. PIVOT, KELLY, J. TORTOCHAUX, D. BELPOMME , Y. HUMBLET, C. DOMENGE, A. JOHNSTON, N. CLENDENINN, C. PENNING, M. SCHNEIDER. A phase III trial of nolatrexed versus methotrexate in patients (pts) with advanced or recurrent squamous cell carcinoma of the head and neck (SCCHN). Proc. Eur. Soc. Med. Oncol., 23rd Congress of the ESMO, 6-10 November 1998 (Abst. 3580) Athens.

20

22. KRAKOWSKI, T. PETIT, L. KAYTALIRE, B. WEBER, M. BEAUDOUIN, J.L. CANON, J. JANSSENS, C. MARTIN, D. BELPOMME . Gemcitabine (GemzarÒ) in combination with Cisplatin (CP) in advanced ovarian cancers (AOC): a phase II study. Proc. ASCO, May 1998, Los Angeles, USA.

23. D. BELPOMME , J. TROTOUX, V. BASSOT, D. AIDAN, M. ELBEZ. Chemocurability of a subset of patients with head and neck squamous cell carcinoma, exclusively treated by short term Cisplatin-Fluorouracil continuous infusion. Proc. ASCO, May 1998, Los Angeles, USA.

24. J. TROTOUX, V. BASSOT, D. AIDAN, M. ELBEZ, D. BELPOMME . Chemocurability of a subset of patients with head and neck squamous cell carcinoma (HNC) exlusively treated by Cisplatin-Fluorouracil (P-FU) induction chemotherapy: a retrospective analysis of 121 cases. Proc. 8th SOMPS, 3-6 February 1998 (Abst. 069), Paris.

25. D. BELPOMME . Gemcitabine and Cisplatin in ovarian cancer. 5th franco-japanese meeting, Institut Gustave Roussy, 19 September 1997, Villejuif.

26. J.F. GILLETTE, C. FERME, N. MOISY, L. MIGNOT, R. SCHACH, J.R. VIGNAUX, J.G. BESNER, G. CAILLE, D. BELPOMME . Double-blind crossover clinical and pharmcokinetic comparison of oral morphine syrup and sustained release morphine sulfate capsules in patients with cancer-related pain. Colloque Médico-Pharmaceutique Franco-Turc, 25-30 May 1997, Ankara, Istambul.

27. D. BELPOMME , I. KRAKOWSKI, M. BEAUDUIN, T. PETIT, J.L. CANON, J. JANSSENS, S. GAUTHIER, A. DE PAUW, V. MOREAU, L. KAYTALIRE. Combinaison Gemcitabine-Cisplatine (GEM-CDDP) en première ligne dans les adénocarcinomes de l’ovaire avancés (AOA) : premiers résultats d’une étude franco-belge de phase II. Proc. 17ème Forum de Cancérologie, 26-27 May 1997, Paris.

28. S. GAUTHIER, N. ROUVERAND, B. COUDERT, B. BRUN, B. ROULLET, J.C. BARATS, N. LAGARDE, F. COLONNA, F.N. MARIE, C. GOUSSET, D. BELPOMME . Une remise en question du modèle de Goldie-Coldman dans les cancers du sein : résultats d’une étude de phase III comparant en première ligne métastatique, l’alternance des deux combinaisons FAC et VMMc sans résistance croisée, à leur administration seule. Proc. 17ème Forum de Cancérologie, 26-27 May 1997, Paris.

29. J. TROTOUX, V. BASSOT, D. AIDAN, M. ELBEZ, D. BELPOMME . Chimiocurabilité d’un sous-groupe de malades atteints de cancers ORL épidermoïdes exclusivement traités par chimiothérapie de type Cisplatine-5-Fluorouracil (P-FU) pour leur tumeur primaire : analyse rétrospective d’une cohorte de 111 cas. Proc. 17ème Forum de Cancérologie, 26-27 May 1997, Paris.

30. D. BELPOMME , I. KRAKOWSKI, M. BEAUDUIN, T. PETIT, J.L. CANON, J. JANSSENS, S. GAUTHIER, A. DE PAUW, V. MOREAU, L. KAYTALIRE. Gemcitabine (GEM) in combination with Cisplatin (CP) in stage III or IV ovarian cancer: preliminary phase II results. Proc. ASCO, May 1997, Denver, USA.

31. D. BELPOMME , S. GAUTHIER, N. ROUVERAND, B. COUDERT, B. BRUN, B. ROULLET, J.C. BARATS, L. GUILLEVIN, M.H. FILIPPI, A. LEROL, N. LAGARDE, C. GOUSSET, ARTAC. Breast Cancer Study Group, Hôpital Boucicaut, Paris. Goldie Coldman hypothesis revisited in Metastatic Breast Carcinoma (MBC): no superiority of first line chemotherapy using the 2 alternate non cross-resistant FAC and VMMc regimens in comparison with each other alone - an ARTAC phase III trial. Proc. 88th AACR meeting, April 1997, San Diego, USA.

32. D. BELPOMME . Cancer : Mythes, Réalités, Espoir. Proc. AFAS 114ème Congrès de l’Association Française pour l’Avancement des Sciences, "Peurs et Espoirs du Troisième Millénaire", 22-24 November 1996, Palais de la découverte, Paris.

33. Y. MERROUCHE, R. BUGAT, R.BRUNET, J.F. SEITZ, P. LUCAS, T.COUROY, J.Y. DOUILLARD, T. BOUILLET, P. PIEDBOIS, Ph. ROUGIER, H. JACOB, D. BELPOMME , V. FABRE, D. MERY-MIGNARD, M. MAHJOUBI. Hight dose Acetorphan (HDA) versus Acetorphan + Lopramide (A+L) in the treatment of CPT-II induced diarrhea (DD): preliminary report of a randomized phase II study in patients (pts) with advanced colorectal cancer (CRC).

34. BONNETERRE, J.L. MISSET, J.P. GUASTALLA, P. VIENS, P. FUMOLEAU, H. ROCHE, I. VAN PRAAGH, B. DUCLOS, L. MAURIAC, M. NAMER, D. BELPOMME , P. KERBRAT, V. TRILLET-LENOIR, D. KHAYAT, J.P. LOTZ, P. BASTIT, N. COLBERT, L. BARNOUIN. Feasability and Safety of Taxotere (TXT) in heavily pretreated metastatic breast cancer (MBC): preliminary report of a multi centre compassionate use program. Proc. ASCO, May 1996, 15, 116 (Abst. 130), Philadelphia, USA.

35. C. TERRET, A. LE CESNE, N. LAGARDE, M. DI PALMA, E. GONCALVES, P. N’DOM, Y. YATAGHENE, C. FUNCK-BRENTANO, J.P. N’GUYEN, J.P. MARINO, B. BESSE, J.P. ARMAND, T. LE CHEVALIER, D. BELPOMME , J.L. MISSET, L D’AGAY, E. BERGER, M. SARKANY, B. GIROUX. S9788 a multidrug resistance (MDR) reversing agent: French phase I studies with 6 hour continuous infusion schedule in combination with chemotherapy in patients with refractory cancer. Proc. AACR, April 1996, 37, 165 (Abst. 1139), Whashington, USA.

21

36. D. BELPOMME . Les nouveaux médicaments en oncologie. 2ème journée de Thérapeutique et Pratique Hospitalière (TPH) : Optimiser les traitements en oncologie, 22-23 March 1996, Faculté de Pharmacie, Paris. T.P.H., Paris.

37. T. FACCHINI, D. BELPOMME , G. KEMP, P. ROSE, B. ROULLET, P. PHILLIPS, B.J. SCHEFFLER, W. OSTER, R.L. CAPIZZI, P.S. SCHEIN. Amifostine (AMI) selectively protects against cumulative toxicities of cyclophosphamide © and Cisplatin (P). Proc. ECCO 8, 29 October - 2 November 1995 (Abst. 500), Paris.

38. D. BELPOMME . Ars Medica Congress on Genetic engineering and gene therapy. 20-21 October 1995, Brussels.

39. MORVAN, M. ESPIE, L. MIGNOT, A. DE ROCQUANCOURT, D. BELPOMME , P. CLOT, F. CALVO, C. GISSELBRECHT, M. MARTY. 15 years follow-up for T4d (inflammatory) breast cancer patients. Proc. ASCO, 31st Annual Meeting, 20-23 May 1995 (Abst.), Los Angeles, USA.

40. D. BELPOMME , E. PUJADE-LAURAINE, S. GAUTHIER, I. KRAKOWSKI, M. FRENAY, M.H. FILIPPI, T. FACCHINI, M.J. GOUDIER, F. GUINET, G. NETTER-PINON, B. ROULLET, Y. BASTION, C. PLATINI, T. DARSE, A. LE ROL, L. MIGNOT, R. RIOU for the ARTAC breast carcinoma study group. Continuous low-dose racemic Verapamil (Vp) significantly increases response rate and survival in patients (pts) treated by VDS and 5-FU (VF) for anthracycline resistant metastatic breast carcinoma (MBC). Interim analysis of an ARTAC phase III study. Proc AACR, 86th Annual Meeting, 18-22 March 1995 (Abst.), Toronto, Canada.

41. KEMP, P. ROSE, J. GLICK, J. LURAIN, B. ROULLET, T. FACCHINI, C.J. MARTIN, D. BELPOMME , E. MITCHELL, B. SCHEFFLER. Selective cytoprotection from the cytotoxicity associated with cyclophosphamide © and Cisplatin (P) ± Amifostine (A): a randomized trial in patients with advanced epithelial ovarian cancer. Proc Society of Gynecologic Oncologists (SGO), 26th Annual Meeting, 19-22 February 1995 (Abst.), San Francisco, USA.

42. M. EL-BEZ, V. BASSOT, P. NAUDO, D. BELPOMME , P. BONFILS, J. TROTOUX. Exclusive chemotherapy in head and neck cancers. 5th SOMPS, 31 January - 3 February 1995 (Abst. 0773), Paris.

43. B. ROULLET, T. FACCHINI, C. MARTIN, P. VENNIN, R. VILLET, S. GAUTHIER, D. BELPOMME , P. PHILLIPS, J. JIMENO, W. OSTER, J. GLICK, R.L. CAPIZZI. An ARTAC (France)/US Bioscience study group. A phase III study evaluating Amifostine (A) Cytoprotection in patients (pts) with advanced ovarian cancer (OVCA) receiving Cisplatin (P) + Cyclophosphamide (C) chemotherapy (CT). Proc. Eur. Soc. Med. Oncol., 19th congress of the ESMO, 18-22 November 1994 (Abst. 0992), Lisbonne.

44. E. PUJADE-LAURAINE, M. PICCART, G. RUSTIN, C. LHOMME, M. GORE, H.W. TEN BOKKEL, P. FUMOLEAU, A. VAN OOSTEROOM, Y.A. VERWEIJ, S. KAYE, D. BELPOMME , M. VAN GLABBEKE, J. WANDERS, B. CHEVALLIER, H. FRANKLIN. Comparison of CA 125 kinetics and WHO criteria to evaluate chemotherapy response ®: an EORTC ovarian cancer (O.C.) study with Proc. Eur. Soc. Med. Oncol., 19th congress of the ESMO, 18-22 November 1994 (Abst. P502) Taxotere (T), Lisbonne.

45. D. BELPOMME , E. PUJADE-LAURAINE, S. GAUTHIER, I. KRAKOWSKI, M. FRENAY, M.H. FILIPPI, T. FACCHINI, M.J. GOUDIER, F. GUINET, G. NETTER-PINON, B. ROULLET, Y. BASTION, C. PLATINI, T. DARSE, A. LE ROL, L. MIGNOT, R. RIOU for the ARTAC breast carcinoma study group. Continuous low-dose racemic Verapamil (Vp) significantly increases response rate and survival in patients (pts) treated by VDS and 5-FU (VF) for anthracycline resistant metastatic breast carcinoma (MBC). Interim analysis of an ARTAC phase III study. 1st International Conference on Reversal of Multidrug Resistance in Cancer, 1-3 September 1994, St Gallen, Switzerland.

46. D. BELPOMME . General clinical and pharmacological properties of Verapamil. Private meeting of ARTAC investigators, 1 June 1994, Paris.

47. E. PUJADE-LAURAINE, M. PICCART, G. RUSTIN, C. LHOMME, M. GORE, H.W. TEN BOKKEL, P. FUMOLEAU, A. VAN OOSTEROOM, Y.A. VERWEIJ, S. KAYE, D. BELPOMME , M. VAN GLABBEKE, J. WANDERS, B. CHEVALLIER, H. FRANKLIN. Comparison of CA 125 kinetics and WHO criteria to evaluate chemotherapy response ®: an EORTC ovarian cancer (O.C.) study with Proc. ASCO, 30th Annual Meeting, 14-17 May 1994 (Abst. 859) Taxotere (T), Dallas, USA.

48. C. CALABRESSE, L. VENTURINI, C. CHOMIENNE, P. VILLA, D. BELPOMME . Butyric acid induces apoptosis of leukemic cells. European School of Heamatology, Euroconference on Apoptosis, 19-20 September 1993, Château Maffliers.

49. D. BELPOMME . Clinical drug trials regulation in Europe. European school of oncology, 6-9 September 1993, Antibes - Sophia Antipolis.

50. D. BELPOMME . Leurubicine, a prodrug of Doxorubicine. Early clinical development of new anticancer drug in France and in Japan (organisator: J.P. Armand), 5 July 1993, Paris.

22

51. D. BELPOMME . Apoptose et thérapeutiques anticancéreuses. INSERM, Unité 29, 2 July 1993, Paris. 52. D. BELPOMME . CACb300 versus CAP in ovarian carcinoma. 1st Workshop in ovarian carcinoma,

(organisator: B. Lund), 15-19 June 1993, Copenhagen. 53. S. BARBEY, C. CALABRESSE, D. BELPOMME , C. CHOMIENNE. Agents de différenciation des

cellules leucémiques et apoptose. Club differenciation et apoptose en thérapeutique oncologique, ARC, (organisator: L. Israel, L. Degos), 27 May 1993, Villejuif.

54. C. CALABRESSE, L. VENTURINI, C. CHOMIENNE, P. VILLA, D. BELPOMME . Butyric acid induces apoptosis of leukemic cells. Proc. AACR, 84th Annual Meeting, 19-22 May 1993 (Abst. 1748), Orlando, USA.

55. S. GAUTHIER, M.C. PINEL, M. De FORNI, B. ROULLET, T. PERNICENI, J. CHAUVERGNE, R. BUGAT, J.H. BAUDET, M.H. FILIPPI, R. BRUNET, C. GENDRE, M. REMY, M.H. LAPORTE, P. MARTEL, M. LE BONNIEC, D. BELPOMME . Familial ovarian carcinoma: analysis of the first cases gathered by the french branch of the Gilda Radner familial ovary cancer registry. Proc. ASCO, 29th Annual Meeting, 15-18 May 1993 (Abst. 877), Orlando, USA.

56. D. BELPOMME , C. CALABRESSE. Apoptose induite par les agents anti-cancéreux : tentatives de modélisation et applications à l’étude de nouveaux dérivés d’acide butyrique. Differenciation et apoptose en thérapeutique oncologique, 28 September 1992, Villejuif.

57. PUJADE-LAURAINE, P. KERBRAT, P. FUMOLEAU, G. PINON, N. GODFROID, M.C. PINEL, M. AZAB, D. BELPOMME . Phase II study of Pazelliptine (PZE) in refractory ovarian carcinoma (OC). Proc. AACR, 83rd Annual Meeting, 20-23 May 1992, 33, 526 (Abst. 3148), San Diego, USA.

58. D. BELPOMME , R. BUGAT, R. RIVES, G. PINON, B. ROULLET, T. FACCHINI, M.C. PINEL, P. HIS, M. CHAZARD, L. LENAZ. Carboplatin versus Cisplatin in association with Cyclophosphamide and Doxorubicine as first line therapy in stage III-IV ovarian carcinoma: results of an ARTAC phase III trial. Proc. ASCO, 28th Annual Meeting, 17-19 May 1992, 11, 227 (Abst. 722), San Diego, USA.

59. J.L. MISSET, M. GIL-DELGADO, P.H. CHOLLET, D. BELPOMME , F. FARGEOT, P. FUMOLEAU. Ten years results of the french trial comparing adriamycin, vincristin, 5-Fluoro-uracile and cyclophosphamide to standard CMF as adjuvant therapy for node positif breast cancer. Proc ASCO, 28th Annual Meeting, 17-19 May 1992, 11, 54 (Abst. 41), San Diego, USA.

60. D. BELPOMME , F. HERITIER. Apoptosis as a common process of induced cell death shared by anti-cancer agents: a new model for drug design. 7th NCI-EORTC symposium on new drugs in cancer therapy, 17-20 March 1992, Amsterdam.

61. P. TRESCA, P. CANAL, J. COUPIER, E. PUJADE-LAURAINE, F. ROUSSEAU, M. MARTY, M. DE FORNI, R. BUGAT, M.H. FILIPPI, J. ROBERT, D. BELPOMME . Leurubicin, a prodrug of doxorubicin: an ARTAC phase I clinical and pharmacokinetic study. 7th NCI-EORTC symposium on new drugs in cancer therapy, 17-20 March 1992, Amsterdam.

62. P.J. SOUQUET, P. FOURNEL, P. TRESCA, N. CHERON, M. FRENAY, R. RIOU, V. TRILLET, W.W. TEN BOKKEL, H. FRANKLIN, A. MAGIS, D. BELPOMME . Results of Vintriptol (VTP) in non small cell bronchus carcinoma (NSCBC) as part of an international multitumor phase II screening program. 7th NCI-EORTC symposium on new drugs in cancer therapy, 17-20 March 1992, Amsterdam.

63. D. BELPOMME , R. BUGAT, M. RIVES, G. PINON, B. ROULLET, T. FACCHINI, M.C. PINEL, P. HIS, M. CHAZARD, L. LENAZ. Carboplatin versus Cisplatin in association with cyclophosphamide and Doxorubicin as first line therapy in stage III-IV ovarian carcinoma: results of an ARTAC phase III trial. 7th NCI-EORTC symposium on new drugs in cancer therapy, 17-20 March 1992, Amsterdam.

64. P. CANAL, J. ROBERT, M. RAMON, R. BAURAIN, P. TRESCA, M. DE FORNI, M. MARTY, E. PUJADE-LAURAINE, R. BUGAT, A. MAGIS, D. BELPOMME . Human pharmacokinetic and pharmacodynamic studies of N-L-Leucy-Doxorubicin, a new anthracycline derivative. Proc. ECCO 6, 27-31 October 1991 (Abst. 1206), Florence.

65. P. TRESCA, J. COUPIER, M. DE FORNI, F. ROUSSEAU, M. MARTY, E. PUJADE-LAURAINE, R. BUGAT, P. HIS, C. PRADY, P. CANAL, A. MAGIS, D. BELPOMME . N-L-Leucyl-Doxorubicin: results of an ARTAC phase I study. Proc. ECCO 6, 27-31 October 1991 (Abst. 1212), Florence.

66. Cl. CHASTANG, B. DAUTZENBERG, R. ARRIAGADA, T. LE CHEVALIER, D. BELPOMME , J. HURDEBOURG, B. LEBEAU, J.P. COQUILLAUD, Ch. FABRE, Ph. CHARVOLIN, R.A. GUERIN. Results of a randomized clinical trial of a post operative chemotherapy (COPAC) in stage II and III resected bronchogenic carcinoma (267 patients). Proc. ECCO 6, 27-31 October 1991 (Abst. 1017), Florence.

67. D. BELPOMME , F. HERITIER. Apoptosis as a common process of induced cell death shared by anti-cancer drugs: a new model for drug design. Proc. 4th International ARTAC Workshop on therapeutic trials in Cancer and AIDS, September 1991 (Abst. 059), Paris. Idem in European Cancer News, 1991.

68. B. DAUTZENBERG, Cl. CHASTANG, R. ARRIAGADA, T. LE CHEVALIER, D. BELPOMME, et al. Is there a role for the post operative chemotherapy in the treatment of stage II-III resected lung cancer ?

23

Results of a randomized trial from the GETCB. Proc. 4th International ARTAC Workshop on therapeutic trials in Cancer and AIDS, Paris, September 1991 (Abst. 057). Idem in European Cancer News, 1991.

69. J.L. MISSET, M. GIL-DELGADO, R. PLAGNE, D. BELPOMME , J. GUERRIN, P. FUMOLEAU, R. METZ, G. MATHE for the OncoFrance group. Ten year results of the French adjuvant trial for Adriamycin (ADM), Vincristin (VCR), Cyclophosphamide (CPM) and 5-Fluorouracile (5FU). Proc. 4th International ARTAC Workshop on therapeutic trials in Cancer and AIDS, September 1991 (Abst. 056), Paris. Idem in European Cancer News, 1991.

70. N. GODFROID, J. METAIS, N. FRETAULT, D. BELPOMME . How to define dose-intensity for drug combinations ? Proc. 4th International ARTAC Workshop on therapeutic trials in Cancer and AIDS, September 1991 (Abst. 043), Paris. Idem in European Cancer News, 1991.

71. P. TRESCA, P. CANAL, J.COUPIER, J. ROBERT, M. DE FORNI, M. MARTY, F. ROUSSEAU, E. PUJADE-LAURAINE, R. BUGAT, M. RAMON, R. BAURAIN, A. MAGIS, D. BELPOMME . Leurubicin, a prodrug of doxorubicin: early results of an ARTAC phase I study. Proc. 4th International ARTAC Workshop on therapeutic trials in Cancer and AIDS, September 1991 (Abst. 028), Paris. Idem in European Cancer News, 1991.

72. D. BELPOMME . Organization and contribution of ARTAC for the clinical development of new anti-cancer molecules in France. Proc. 4th International ARTAC Workshop on therapeutic trials in Cancer and AIDS, September 1991 (Abst. 024), Paris. Idem in European Cancer News, 1991.

73. D. BELPOMME , R. BUGAT, M. RIVES, G. PINON, B. ROULLET, T. FACCINI, M.C. PINEL, P. HIS, M. CHAZARD, L. LENAZ. Carboplatin versus Cisplatin in association with cyclophosphamide and Doxorubicin as first line therapy in stage III-IV ovarian carcinoma: results of an ARTAC phase III trial. Proc. 4th International ARTAC Workshop on therapeutic trials in Cancer and AIDS, September 1991 (Abst. 008), Paris. Idem in European Cancer News, 1991.

74. M.C. PINEL, T. FACCHINI, R. FAVRE, D. CUPISSOL, R. METZ, T. KLEIN, C. PLATINI, C. PRADY, P. TRESCA, P. HERAIT, D. BELPOMME . An ARTAC reinvestigation of Peplomycin in epidermoid head and neck carcinoma (HNC). Proc. Amer. Soc. Clin. Oncol., 1991, 10, 201 (Abst. 667).

75. P. CANAL, J. ROBERT, M. RAMON, R. BAURAIN, P. TRESCA, D. BELPOMME . Pharmacokinetic study of N-L-Leucyl-Doxorubicin, a new phase I agent. Proc. Amer. Assoc. Cancer Res., 1991, 32, 178 (Abst. 1064).

76. D. BELPOMME . Vinorelbine in breast carcinoma: results of an ARTAC phase II trial with special reference to dose intensity and cross resistance with classical drugs. Proc. 3rd International Congress on neoadjuvant chemotherapy, 1991 (Abst. C5).

77. D. BELPOMME . Le traitement spécifique des cancers métastatiques : de la biologie moléculaire aux nouvelles perspectives cliniques. Proc. 3ème Congrès National de la Société Française de Cancérologie Privée, 1991 (Abst.).

78. W.W. TEN BOKKEL HUININK, D. BELPOMME , H. FRANKLIN, P. FUMOLEAU, J. VERWEIJ. Phase II screening program of Vintriptol in breast cancer, melanoma, colorectal cancer and lung cancer. 15th European Soc. Medical Oncol. Congress, Annals oncology, December 1990, 1, 37 (supp. 1) (Abst. P5-14), Copenhagen.

79. ROCHE, P. FUMOLEAU, P. TRESCA, G. PINON, D. SERIN, F.N. MARIE, M. DELGADO, D. BELPOMME . Vinorelbine a new active drug in breast carcinoma: results of an ARTAC phase II trial. XV European Soc. Medical Oncol. Congress, Annals oncology, December 1990, 1, 36 (supp. 1) (Abst. P.5-12), Copenhagen.

80. T. FACCHINI, R. FAVRE, D. CUPISSOL, R. METZ, T. KLEIN, C. PLATINI, J.M.VANNETZEL, M.C. PINEL, C. PRADY, P. HERAIT, D. BELPOMME . A reinvestigation of Peplomycin in epidermoid head and neck carcinoma (HNC): an ARTAC phase II trial. 15th European Soc. Medical Oncol. Congress, Annals oncology, December 1990, 1, 37 (supp. 1) (Abst. P.5-13), Copenhagen.

81. M. FRENAY, J.P. BIZZARI, C. PRADY, R. RIOU, T. FACCHINI, J.P. HOMASSON, J.F. SZTERMER, B. ROULLET, J. PENY, M.C. PINEL, D. BELPOMME . Potential activity of Fotemustine in brain metastasis (BM) originated from tumors other than melanoma: preliminary results of an ARTAC cooperative phase II screening program. XV European Soc. Medical Oncol. Congress, Annals oncology, December 1990, 1, 122 (supp. 1) (Abst. W.12-2), Copenhagen.

82. P. TRESCA, A. MAGIS, F. ROUSSEAU, L. CHAUVENET, M. DE FORNI, M. MARTY, E. PUJADE-LAURAINE, R. BUGAT, P. CANAL, J. ROBERT, P. HIS, R. BAURAIN, D. BELPOMME . N-L-Leucyl-Doxorubicin: an ARTAC coordinated phase I study with inter and intra-patient dose step escalation. 15th European Soc. Medical Oncol. Congress, Annals oncology, December 1990, 1, 41 (supp. 1) (Abst. P.5-32), Copenhagen.

24

83. P. TRESCA, P. FUMOLEAU, H. ROCHE, G. PINON, D. SERIN, F.N. MARIE, M. DELGADO, D. BELPOMME . Vinorelbine, a new active drug in breast carcinoma: results of an ARTAC phase II trial. 13th Annual San Antonio Breast Cancer Symposium, November 1990, San Antonio, USA.

84. D. BELPOMME , N. MOISY, J.G. BESNER, G. CAILLE, P. GEHANNO, et al. Comparative bioavailability and clinical study of a new sustained release morphine sulfate (E-SRMS): an ARTAC randomized double blind study. 3rd Annual Congress on International consensus on Supportive Care in Oncology (ISCO), August 1990, Brussels.

85. F.N. MARIE, N. MOISY, J. MEYNADIER, J. DUBRUJEAUD, I. KRAKOWSKI, D. COLLARD, P. GEHANNO, P. SCHNEIDER, B. DEBREGEAS, D. BELPOMME . Administration of a new sustained release morphine sulfate (E-SRMS) per os or through a gastric tube: a further ARTAC study. 3rd Annual Congress on International consensus on Supportive Care in Oncology (ISCO), August 1990, Brussels.

86. D. BELPOMME , C. GISSELBRECHT, K. HACENE, F. HERITIER, G. MICHAUD, M. MARTY, M.H. FILIPPI, G. PINON, E. PUJADE-LAURAINE, J. MARAL. Vindesine (V), Mitoxantrone (M), and Mitomycine C (MC), (VMMc) in metastatic breast carcinoma (MBC): an ARTAC study with special reference to drug resistance. Proc. 15th International Cancer Congress UICC, August 1990, Hambourg.

87. MC. PINEL, R. BUGAT, A. LE ROL, G. PINON, B. COIFFIER, T. FACCHINI, B. ROULLET, M. RIVES, R. VILLET, D. CUPISSOL, D. MARANINCHI, F.N. MARIE, V. VERITE, M. CHAZARD, D. BELPOMME . Carboplatin (Cd) or Cisplatin in combination with cyclophamide and Adriamycin in advanced ovarion carcinoma (AOC): interim analysis of an ARTAC phase III randomized trial. Proc. 15th International Cancer Congress UICC, August 1990, Hambourg.

88. R. METZ, Ph. MARTIN, T. FACCHINI, F. HECHT, O. STERCKERS, M. GRANDJEAN, MC. PINEL, M. CHAZARD, D. BELPOMME . Carboplatin and Methotrexate (Cb-M) as first line adjuvant chemotherapy in epidermoid head and neck carcinoma: an ARTAC phase II trial. Proc. 15th International Cancer Congress UICC, August 1990, Hambourg.

89. HERITIER, R. FAVRE, R. METZ, T. FACCHINI, D. CUPISSOL, T. KLEIN, C. PLATINI, J.M. VANNETZEL, M.C. PINEL, H. HERAIT, D. BELPOMME . A reinvestigation of Peplomycin in epidermoid head and neck carcinoma (HNC): an ARTAC phase II trial. Proc. 15th International Cancer Congress UICC, August 1990, Hambourg.

90. P. TRESCA, MC. PINEL, G. PINON, MJ. GOUDIER, B. COIFFIER, M.H. FILIPPI, JP. BLAISE, A. GOUPIL, B. ROULLET, D. BELPOMME . Navelbine and Hexamethyl-Melamine (H) (N-H) as second or further line chemotherapy regimen in advanced ovarian carcinoma: an ARTAC phase II study. Proc. 15th International Cancer Congress UICC, August 1990, Hambourg.

91. PINON, P. FUMOLEAU, H. ROCHE, D. SERIN, H. BONNEFOI, T. FACCHINI, F. GUINET, P. TRESCA, M. DELGADO, D. BELPOMME . Navelbine as second line therapy in metastatic breast carcinoma (MBC): an ARTAC phase II trial. Proc. 15th International Cancer Congress UICC, August 1990, Hambourg.

92. N. CHERON, N. MOISY, J. MEYNADIER, J. DUBRUJEAUD, M.H. FILIPPI, I. KRAKOWSKI, D. COLLARD, P. GEHANNO, P. SCHNEIDER, B. DEBREGEAS, D. BELPOMME . Ethypharm sustained release Morphine sulfate (E-SRMS): a further ARTAC/F003 study of tolerance and efficacy. Proc. 15th International Cancer Congress UICC, August 1990, Hambourg.

93. M.H. FILIPPI, F. HERITIER, D. BELPOMME . Is chemoresistance a purely selective process ? Arguments for an authentic therapeutically induced secondary resistance (ATISR). Proc. 15th International Cancer Congress UICC, August 1990, Hambourg.

94. D. BELPOMME . Chimiothérapie de première et deuxième intention dans les cancers de l’ovaire : l’expérience de l’ARTAC. Symposium de la société francophone de cancérologie, June 1990, Paris.

95. LEROL, M.H. FILIPPI, F. PAPPO, A. OLIVIER, D. BELPOMME . Fluorouracile-Acide folinique dans le traitement des cancers colorectaux métastasés. Résultats à 9 ans. 10ème Forum de cancérologie (AFEC), June 1990, Paris.

96. D. BELPOMME . Chimiothérapie adjuvante, néoadjuvante et peri-opératoire : nouveaux concepts. Symposium des sociétés française de cancérologie privée et belge de sénologie "Diagnostic et traitement des cancers du sein en 1990", May 1990, Brussels.

97. M. SCHNEIDER, P. FUMOLEAU, P. CAPPELAERE, J.P. ARMAUD, C. LHOMME, J. CHAUVERGNE, A. GOUPIL, R. METZ, D. BELPOMME (sponsor). Phase II Pirarubicin (THP-ADM) of the clinical screening Group (CSG). Proc. American Assoc. Cancer Res., 1990, 31, 207.

98. P. FUMOLEAU, H. ROCHE, G. PINON, D. SERIN, H. BONNEFOI, T. FACCHINI, F. GUINET, P. TRESCA, M. DELGADO, D. BELPOMME . Navelbine (N) as second line chemotherapy in metastatic breast carcinoma (MBC): an ARTAC phase II trial. Proc. American Assoc. Cancer Res., 1990, 31, 207.

99. C. PINEL, G. PINON, MJ. GOUDIER, B. COIFFIER, M.H. FILIPPI, JP. BLAISE, A. GOUPIL, B. ROULLET, D. BELPOMME . Navelbine and Hexamethyl-Melamine (H) (N-H) as second or further line

25

chemotherapy regimen in advanced ovarian carcinoma: an ARTAC phase II study. Proc. American Soc. Clin. Oncol., 1990, 9, 166.

100. D. BELPOMME . Some biological and clinical aspects of chemoresistance: on going studies at the ARTAC. Seminar at the Upjohn company, March 1990, Kalamazoo, USA.

101. N. CHERON, N. MOISY, J. MEYNADIER, J. DUBRUJEAUD, M.H. FILIPPI, I. KRAKOWSKI, D. COLLARD, P. GEHANNO, P. SCHNEIDER, B. DEBREGEAS, D. BELPOMME . Ethypharm sustained release Morphine sulfate (E-SRMS): a further ARTAC/F003 study of tolerance and efficacy. 2nd International symposium on supportive care in cancer patients, February-March 1990, St Gallen, Switzerland.

102. D. BELPOMME , M.C. PINEL, P. TRESCA, G. PINON, M.J. GOUDIER, B. COIFFIER, M.H. FILIPPI, A. GOUPIL, B. ROULLET, T. FACCHINI, L. MIGNOT, F. HERITIER, M. DELGADO. Study of the combination Vinorelbine-Hexamethylmélamine (V-H) in advanced ovarian adenocarcinomas, preliminary results of a phase I-II trial. In the book "Navelbine actualités et perspectives", P. F. Médicament Ed., 1990, Paris.

103. D. BELPOMME . Experiencias clinicas con Sulfato de Morphine oral de liberation lenta. 10th Congresso Argentino del dolor, November 1989, Buenos Aires, Argentina.

104. D. BELPOMME , M.C. PINEL, et al. Etude phase II de l’association Navelbine (N)-Hexamethyl-Mélamine (H) dans les cancers de l’ovaire en phase avancée. Symposium Navelbine, P.F. Médicament, November 1989, Biarritz.

105. N. MOISY, N. CHERON, J. MEYNADIER, J. DUBRUJEAUD, M.H. FILIPPI, I. KRAKOWSKI, D. COLLARD, P. GEHANNO, P. SCHNEIDER, B. DEBREGEAS, D. BELPOMME . Ethypharm sustained release morphine sulfate (E-SRMS): a further ARTAC/F003 study of tolerance and efficacy. 3rd ARTAC Workshop on therapeutic trials in oncology. Cancer Communication, October 1989, 3, 306, Paris.

106. G. PINON, MC. PINEL, MJ. GOUDIER, B. COIFFIER, M.H. FILIPPI, JP. BLAISE, A. GOUPIL, B. ROULLET, P. COLIN, M. DELGADO, D. BELPOMME . Navelbine and Hexamethyl-Melamine (H) (N-H) as second or further line chemotherapy regimen in advanced ovarian carcinoma: an ARTAC phase II study. 3rd ARTAC Workshop on therapeutic trials in oncology. Cancer Communication, October 1989, 3, 306, Paris.

107. D. BELPOMME . Chemoresistance: biological mechanisms and therapeutic implications. 3rd ARTAC Workshop on therapeutic trials in oncology. Cancer Communication, October 1989, 3, 306, Paris.

108. D. BELPOMME , F. HERITIER. Concept transfer from biology to clinical oncology. 3rd ARTAC Workshop on therapeutic trials in oncology. Cancer Communication, October 1989, 3, 305, Paris.

109. M.C. PINEL, P. TRESCA, D. BELPOMME . Good clinical practice in oncology. 3rd ARTAC Workshop on therapeutic trials in oncology. Cancer Communication, October 1989, 3, 304, Paris.

110. JC. BESNER, G. CAILLE, P. GEHANNO, JF. GILLETTE, L. MIGNOT, R. SCHACH, JR. VIGNAUX, C. FERME, P. SCHNEIDER, D. BELPOMME . Comparative bioavailability and clinical study of a new sustained release preparation of Morphine Sulfate, an ARTAC study. Proc. ECCO 5, 3-7 September 1989 (Abst. 0527), London.

111. ROCHE, MC. PINEL, G. PINON, C. CUPISSOL, J. MARAL, D. ROMAIN, D. BELPOMME . BRL 43694, nouvel antagoniste des récepteurs 5HT3 : étude de la durée de l’effet antiémétique maximal près administration d’une dose unique. 10ème Forum de Cancérologie (AFEC), June 1989, Paris.

112. R. METZ, Ph. MARTIN, T. FACCHINI, M.GRANDJEAN, F. HECHT, O. STERCKERS, MC. PINEL, M. CHAZARD, D. BELPOMME . Chimiothérapie néodjuvante des cancers épidermoides de la tête et du cou : étude de l’association Carboplatine-Méthotrexate. 10ème Forum de Cancérologie (AFEC), June 1989, Paris.

113. D. BELPOMME , F. HERITIER, C. RESSAYRE. Goldie Coldman hypothesis revisited: an induction-selection theory of chemoresistance. Proc. Am. Soc. Clin. Onc., May 1989 (Abst. 316), San Francisco, USA.

114. C. RESSAYRE, CM. RIVA, Y. BARRA, Y. CARCASSONNE, D. BELPOMME , YM. RUSTUM. Computation of individual dosage regimen of Cytosine Arabinoside (ARA-C) based on preclinical data. Proc. American Assoc. Cancer Res., May 1989 (Abst. 2144), San Francisco, USA.

115. D. BELPOMME . Is chemoresistance a purely selective process ? Arguments for an authentic therapeutically induced secondary resistance (ATISR). Proc. EORTC foundation, International Symposium, Prospects of oncological clinical research, 1989, Paris.

116. J.F. GILLETTE, J.G. BESNER, G. CAILLE, P. GEHANNO, R. SCHACH, J.R. VIGNAUX, C. FERME, J. MEYNADIER, P. SCHNEIDER, D. BELPOMME . Pharmacokinetical and clinical study of a new sustained release preparation of morphine sulfate: an ARTAC study. Proc. 2nd International Symposium of the Israel Pain Association, 1989, Herzliya, Israel.

26

117. R. METZ, Ph. MARTIN, T. FACCHINI, F. HECHT, O. STERCKERS, MC. PINEL, M. CHAZARD, D. BELPOMME . Carboplatin and Methotrexate (Cb-M) as first line adjuvant chemotherapy in epidermoid head and neck carcinoma: an ARTAC phase II trial. Proc. 6th NCI-EORTC Symposium on new drugs in cancer therapy, March 1989 (Abst.), Amsterdam.

118. MC. PINEL, R. BUGAT, D. BELPOMME , G. PINON, B. COIFFIER, T. FACCHINI, et al. Carboplatin replacing Cis-Platinum for the treatment of advanced ovarian carcinoma: first interim analysis of a randomized phase III trial comparing CAP and CACb-300: an ARTAC study. Proc. 6th NCI-EORTC Symposium on new drugs in cancer therapy, March 1989 (Abst.), Amsterdam.

119. JG. BESNER, G. CAILLE, B. DEBREGEAS, P. GEHANNO, A. LE FESVRE, L. MIGNOT, JR. VIGNAUX, P. SCHNEIDER, D. BELPOMME . Comparative bioavailability and clinical study of a new sustained release preparation of morphine sulfate. Proc. 6th NCI-EORTC Symposium on new drugs in cancer therapy, March 1989 (Abst.), Amsterdam.

120. D. BELPOMME , H. ROCHé, J. MARAL, G. PINON, P. BOUFFETTE, D. CUPISSOL, M.C. PINEL, D. ROMAIN. A further study of BRL 43694: Duration of maximal antiemetic effects of a single dose. Proc. 6th NCI-EORTC Symposium on new drugs in cancer therapy, March 1989 (Abst.), Amsterdam.

121. C. RESSAYRE, A. ILIADIS, D. BELPOMME . Pharmacokinetic modeling of an anticancer drug (5’d FUR) and metabolites (5-FU, FUH2). Proc. 6th NCI-EORTC Symposium on new drugs in cancer therapy, March 1989 (Abst.), Amsterdam.

122. H. ROCHE, MC. PINEL, G. PINON, C. CUPISSOL, J. MARAL, D. ROMAIN, D. BELPOMME . An effective 5HT3 antagonist (BRL 43694) for the control of CDDP induced emesis resistant to standard therapy. Proc. European Soc. Medical Oncol., 13th congress of the ESMO, 1988 (Abst.), Lugano.

123. R. METZ, Ph. MARTIN, T. FACCHINI, F. HECHT, O. STERCKERS, MC. PINEL, M. CHAZARD, D. BELPOMME . Carboplatin and Methotrexate (Cb-M) as first line néoadjuvant chemotherapy in advanced III-IV epidermoid head and neck carcinoma: a phase II trial. Proc European Soc. Medical Oncol., 13th congress of the ESMO, 1988 (Abst.), Lugano.

124. D. BELPOMME , J. MARAL, M.H. FILIPPI, F. HERITIER, F.N. MARIE. Frequent and intensive recalcification of breast carcinoma bone metastasis with the association of Mitoxantrone and 2-methyl-9-hydroxyelliptinium (M-E): a preliminary study. Proc. European Soc. Medical Oncol., 13th congress of the ESMO, 1988 (Abst.), Lugano.

125. D. BELPOMME , J. MARAL, C. VERGELY-POWELS, M.F. POUPON, L. ISRAEL. Goldie-Coldman hypothesis revisited: an induction theory of chemoresistance. 2nd International Congress on neo-adjuvant chemotherapy, February 1988 (Abst.), Paris.

126. D. BELPOMME . La Mitoxantrone dans les cancers du sein : étude de la combinaison VMMc. 2ème ARTAC Workshop sur "les bonnes pratiques cliniques et l’expérimentation thérapeutique en cancérologie", 1987, Paris.

127. D. BELPOMME . L’obstacle de la résistance en chimiothérapie. 2ème ARTAC Workshop sur "les bonnes pratiques cliniques et l’expérimentation thérapeutique en cancérologie", 1987, Paris.

128. D. BELPOMME , C. GISSELBRECHT, M. MARTY, K. HACENE, P. BOUFFETTE, G. NETTER-PINON, E. PUJADE-LAURAINE, L. MIGNOT, J. MARAL. Les cancers du sein métastasés sont-ils potentiellement curables par chimiothérapie ? Etude d’une nouvelle combinaison (VMMc) associant Vindésine, Mitoxantrone et Mitomycine. Société française de gynécologie, 1987, Paris.

129. R. BUGAT, Ph. MARTIN, M. NAMER, G. NETTER-PINON, D. BELPOMME , P. DUFOUR, M.C. SUDRE-PINEL, M. CHAZARD. Apport du Carboplatine dans le traitement des adénocarcinomes ovariens de stades FIGO III, IV : étude de faisabilité de la combinaison CACb (Cyclophosphamide, Adriamycine et Carboplatine). Sociéte française de gynécologie, 1987, Paris.

130. D. BELPOMME , C. GISSELBRECHT, M. MARTY, K. HACENE, et al. Chimiorésistance et cancers du sein métastasés : déductions thérapeutiques basées sur l’étude de l’association VMMc administrée chez des malades antérieurement traitées ou non par une combinaison de type FAC. Société française de sénologie et de pathologie mammaire, 1987, Avignon.

131. D. BELPOMME , B. DAUTZENBERG, J.M. BRECHOT. Essai randomisé testant l’apport de la chimiothérapie dans les cancers bronchiques métastasés non à petites cellules (protocole = 02 CB 84) : les causes d’un échec. Symposium de la société de pneumologie de langue française, 1987, Marseille.

132. D. BELPOMME , F.N. MARIE, M.C. SUDRE-PINEL, J. DEBEIR, F. CHEIX. L’ARTAC, un nouvel outil de la recherche cancérologique : son rôle dans la communication scientifique. Symposium "Information et Communication en cancérologie, outils et techniques", ONCOBA, May 1987, Paris - La Villette.

133. D. BELPOMME . Long remissions with Mitoxantrone, Vindesine and Mitomycine C in metastatic breast cancer. Symposium LEDERLE, 1987, Madrid.

27

134. DEBEIR, D. BELPOMME . L’Interféron Gamma en cancérologie : mécanismes d’action et premiers résultats des essais cliniques précoces. 7ème Forum de Cancérologie (AFEC), 1987, Paris.

135. Ph. MARTIN, R. BUGAT, M. NAMER, G. NETTER-PINON, D. BELPOMME , P. DUFOUR, D. CUPISSOL, H. NAMAN, K. POUZIN, M.C. SUDRE-PINEL, M. CHAZARD. Carboplatine et adénocarcinomes ovariens : étude de faisabilité de la combinaison CACb (Cyclophosphamide, Adriamycine, Carboplatine) dans les stades FIGO III, IV. 7ème Forum de cancérologie (AFEC), 1987, Paris.

136. D. BELPOMME , C. GISSELBRECHT, K. HACENE, M. MARTY, G. NETTER-PINON, E. PUJADE-LAURAINE, A. LE ROL, C. GEORGE, J. MARAL. Longue durée des réponses induites par l’association Vindésine (V), Mitoxantrone (M), et Mitomycine C (Mc) (VMMc) dans les cancers du sein métastasés. 7ème Forum de cancérologie (AFEC), 1987, Paris.

137. R. BUGAT, Ph. MARTIN, M. NAMER, G. NETTER-PINON, D. BELPOMME , P. DUFOUR, H. NAMAN, K. POUZIN, M.C. SUDRE-PINEL, M. CHAZARD. A pilot study of Carboplatin plus Cyclophosphamide and Doxorubicin in advanced ovarian carcinoma. Proc. ECCO 4, 1987 (Abst.), Madrid.

138. D. BELPOMME , C. GISSELBRECHT, K. HACENE, F. HERITIER, G. MICHAUD, M. MARTY, M.H. FILIPPI, et al. A phase II trial of Vindésine (V), Mitoxantrone (M) and Mitomycine C (VMMc) in metastatic breast carcinoma (MBC) with special reference to drug resistance. Proc. ECCO 4, 1987 (Abst.), Madrid.

139. D. BELPOMME , F.N. MARIE, J. DEBEIR, M. SUDRE-PINEL, F. HERITIER, F. CHEIX. ARTAC, a new tool in cancer research. 6th International meeting of pharmaceutical physicians, 1987, Brighton.

140. D. BELPOMME , C. GISSELBRECHT, M. MARTY, V. COUR, F. HERITIER, A. LE ROL, L. MIGNOT, J. MARAL. Long duration of response induced by Vindésine (V), Mitoxantrone (M), and Mitomycine C (Mc), (VMMc), in metastatic breast carcinoma (MBC). Proc. American Soc. Clin. Oncol. 1987, 6, 58 (Abst. 224).

141. L. ISRAEL, J.L. BREAU, D. BELPOMME , J. AGUILERA. Cisplatinum based combination chemotherapy protocols for 106 consecutive patients with untreated stage III-IV ovarian carcinoma. Proc. American Soc. Clin. Oncol. 1987, 6, 119 (Abst. 466).

142. D. BELPOMME . Cancer et prévention Symposium "La prévention en 1987" (M. CLOAREC, R. MOATTI), April 1987, Paris.

143. D. BELPOMME . Les nouvelles perspectives dans la gestion des essais thérapeutiques. 1er ARTAC Workshop sur "les bonnes pratiques cliniques et l’expérimentation thérapeutique en cancérologie", 1986, Villejuif.

144. D. BELPOMME . Les cancers broncho-pulmonaires : acquisitions récentes et nouvelle approche multidisciplinaire. Les protocoles d’essais thérapeutiques en cours. 2ème journée de cancérologie de Charlebourg, 1986, Neuilly.

145. D. BELPOMME . Roféron-A in renal cell cancer. Investigators meeting, Laboratoires Roche, 1986 (Abst.), Nice.

146. D. BELPOMME . Perspectives dans le développement clinique des nouvelles molécules anticancéreuses. 4ème réunion annuelle de l’Association Française d’Oncologie (AFO), Cannes 1986 (Abst.).

147. LE ROL, M.H. FILIPPI, A. OLIVIER, E. RENE, D. BELPOMME . Association de 5-Fluorouracile-acide folinique pour le traitement des cancers digestifs métastasés. 5 Fluorouracile : nouveaux développements. Laboratoires Roche, Symposium, 1986 (Abst.), Neuilly.

148. D. BELPOMME , V. COUR, C. GISSELBRECHT, A. LE ROL, L. MIGNOT, M. MARTY, J. MARAL. Longues remissions induites par la chimiothérapie dans les cancers du sein métastasés : valeur de l’association Mitoxantrone, Eldésine et Mitomycine C (MEM). Journées françaises d’études sur la Novantrone. Laboratoires LEDERLE, Symposium, 1986 (Abst.).

149. D. BELPOMME , M. SCHOENWALD. Interférons et Cancers : revue des essais thérapeutiques actuels. 4ème Réunion des interféronistes de langue française, 1986 (Abst.), Annecy.

150. R.A. GUERIN, C. CHASTANG, B. DAUTZENBERG, T. LE CHEVALLIER, D. BELPOMME , et al. A study of GETCB. First interim analysis of a randomized clinical trial of postoperative chemotherapy (COPAC), in resected bronchogenic carcinoma (244 patients). Congrès de la Socitété Européenne de pneumologie, 1986 (Abst.), Paris.

151. R.A. GUERIN, C. CHASTANG, R. ARRIAGADA, B. LEBEAU, J.P. COQUILLAUD, M. HURDEBOURG, D. BELPOMME , et al. A study of GETCB. A randomized clinical trial of postoperative chemotherapy (COPAC) in stage II and III resected bronchogenic carcinoma (224 patients). Proc. 12th Annual Meeting ESMO, 1986, (Abst. A 35, 137), Nice.

152. D. BELPOMME , F. PAPPO, K. HACENE, G. NETTER-PINON, E. PUJADE- LAURAINE, C. GISSELBRECHT, L. MIGNOT. Advanced ovarian carcinoma: new therapeutic approchoaches based on

28

tumoral residum analysis at staging and second look laparatomy. Proc. 12th Annual Meeting ESMO, 1986, (Abst. A 35, 19), Stockholm.

153. R. PLAGNE, J.L. MISSET, D. BELPOMME , J. GUERIN, B. LEMEVEL, R. METZ, et al. BCG adjuvant immunotherapy after adjuvant chemotherapy for operable breast cancer. A Group Inter France, randomized trial. Proc. ASCO 1986, 23, 157 (Abst. 617).

154. D. BELPOMME , F.N. MARIE, M.C. SUDRE-PINEL. L’ARTAC, nouvel outil de la recherche cancérologique, 1st ARTAC Workshop sur "les bonnes pratiques cliniques et l’expérimentation thérapeutique en cancérologie". Cancer Communication, 1986, Villejuif.

155. D. BELPOMME . Cancers de l’ovaire : le point de vue du chimiothérapeute. Première journée de cancérologie de Charlebourg, 1985, Neuilly.

156. M.C. DAZZA, M. VUPILLAT, F. PAPPO, A. LE ROL, F.HERITIER, D. BELPOMME . Clinical usefulness of CA-199 and CA-125 as markers in solid tumors as compared with Cea. Proc. 13th Annual Meeting of the international society for oncodevelopmental biology and medecine, 1985 (Abst. H-16), Paris.

157. D. BELPOMME . La qualité de la vie, chez les malades atteints de cancers bronchiques évolués : premiers résultats d’une étude multicentrique randomisée (=02CB 84). Symposium AFEC "Qualité de vie des cancéreux", December 1985, (Abst.), Paris.

158. E. PUJADE-LAURAINE, C. GISSELBRECHT, D. BELPOMME , L. MIGNOT, A. LE ROL, A. BERNADOU, M. MARTY. Response to Mitomycine C (M), Doxorubicin (A), and intermediate doses of Methotrexate (Me) in resistant metastatic breast carcinoma: role of prior Doxorubicin therapy. Proc. ECCO 3, 1985, p. 170 (Abst. 654), Stockholm.

159. J.L. MISSET, M. DELGADO, R. PLAGNE, D. BELPOMME , J. GUERRIN, P. FUMOLEAU, R. METZ, G. MATHE. Five years results of the french adjuvant trial for breast cancer comparing CMF to a combination of Adriamycin (ADM), Vincristine (VCR), Cyclophosphamide (CPM) and 5-Fluorouracile (5-FU). Proc. ECCO 3, 1985, p. 167. (Abst. 641), Stockholm.

160. D. BELPOMME , F. PAPPO, A. LE ROL, F. HERITIER, C. GISSELBRECHT, M. MARTY, E. PUJADE-LAURAINE, G. NETTER-PINON, J. SENEZE. Systemic post chemotherapy surgical laparotomy in advanced ovarian carcinoma: improvement in tumor removal and therapeutic decision making. Proc. ECCO 3, 1985, p.120. (Abst. 452), Stockholm.

161. D. BELPOMME , C. CHANY. L’Interféron Alpha en cancérologie : résultats des études cliniques récentes. Workshop, 1985, Amsterdam.

162. L. MIGNOT, F. MORVAN, M. ESPIE, D. BELPOMME , A. GORINS. Les cancers du sein en poussée évolutive : à propos de 71 cas traités par le groupe Saint-Louis-Bichat-Beaujon. Société française de gynécologie, 1984, Paris.

163. LE ROL, D. BELPOMME . Chimiothérapie des cancers bronchiques anaplasiques à petites cellules : expérience à partir d’une série de 85 malades. Journées française de pneumologie, 1984, Nice.

164. D. BELPOMME . Etude sur la qualité de vie des malades atteints de cancers bronchiques non anaplasiques à petites cellules traités par chimiothérapie. Journées françaises de pneumologie, 1984, Nice.

165. D. BELPOMME , F. PAPPO, C. GISSELBRECHT, G. NETTER-PINON, M. MARTY, M. LEVARDON, J. SENEZE. Chimiothérpie des adénocarcinomes de l’ovaire avancés stade FIGO III-IV par la combinaison FAP : résultats chez 65 malades et comparaison avec trois protocoles antérieurs. Société Française de Gynécologie, 1984, Paris.

166. D. BELPOMME , L. MIGNOT, E. PUJADE-LAURAINE, A. LE ROL, M. MARTY, C. GISSELBRECHT, F.N. MARIE. Essai phase II d’une association de 2-Methyl-9-Hydroxy-Elliptinium et d’Etoposide dans les localisations osseuses de cancers du sein. 4th Forum de Cancérologie (AFEC), 1984, Paris.

167. L. MIGNOT, D. BELPOMME , E. PUJADE-LAURAINE, F. HERITIER, A. LE ROL, M. MARTY, F.N. MARIE. A combination of 2-Methyl-9-Hydroxy-Elliptinium (E) and Etoposide (VP) in resistant breast cancer bone metastasis: a phase II clinical trial. Proc. 10th Annual Meeting ESMO, 1984 (Abst. 184), Nice.

168. LE ROL, C. GISSELBRECHT, G. TOBELEM, Y. CURRAN, F. HERITIER, F. PAPPO, D. BELPOMME . An attempt to improve VAC based induction chemotherapy in small cell lung cancer: results of 3 consecutive trials in 86 patients. Proc. 10th Annual Meeting ESMO, 1984 (Abst. 159), Nice.

169. C. GISSELBRECHT, D. BELPOMME , L. MIGNOT, F. MORVAN, M. MARTY. Stratégie thérapeutique dans les adénocarcinomes ovariens. 2ème Journée sur la Fertilité, 1983, 54 (Abst.), Paris.

170. D. BELPOMME , F. PAPPO. Chimiothérapie des adénocarcinomes ovariens. IIème journée sur la Fertilité, 1983, 53 (Abst.), Paris.

29

171. D. BELPOMME , E. PUJADE-LAURAINE, Z. MIGNOT. Chimiosensibilité et pronostic des cancers du sein disséminés, classés selon leurs localisations métastatiques : étude de 100 cas. 3ème Forum de Cancérologie (AFEC), 1983 (Abst.), Paris.

172. D. BELPOMME , C. MASSON, F. PAPPO, A. LE ROL, F. MANCILLA, R. DUTRUEL. Le point de vue des malades face au problème de la vérité. Congrès Européen "Les cancers avant, pendant, après", Ligue Française contre le Cancer, 1983, 59 (Abst.), Paris.

173. G. MATHE, J.L. MISSET, M. DELGADO, R. PLAGNE, D. BELPOMME , J. GUERRIN, P. FUMOLEAU, R. METZ. A randomized control study of breast cancer adjuvant chemotherapy comparing CMF and AVCF. Proc. ECCO 2, 1983 (Abst. 03-75), Amsterdam.

174. E. PUJADE-LAURAINE, D. BELPOMME , M. MARTY, J.B. TRUC, P. POITOUT, A. BERNADOU. Treatment of advanced squamous cervical cancer in a pilot study with COPAC combination chemotherapy. Proc. ECCO 2, 1983 (Abst. 05-36), Amsterdam.

175. D. BELPOMME , H. GAUTIER, M. MARTY, C. CHASTANG. Platinum - based combination chemotherapy in advanced bronchus carcinoma of epidermoid or large cell undifferentiated type. Proc. ECCO 2, 1983 (Abst. 10-43), Amsterdam.

176. D. BELPOMME . Apport de la chronothérapie en chimiothérapie anticancéreuse. Colloque chronothérapie et pompes, December 1982, Bordeaux.

177. L. MIGNOT, D. BELPOMME , M. ESPIE et al. Les cancers inflammatoires du sein. 10ème journée sur la Fertilité, 1982 (Abst.), Paris.

178. D. BELPOMME , C. GISSELBRECHT, J.C. THALABARD, et al. Combinaisons chimiothérapiques dans les cancers de l’ovaire évolués de stade FIGO III-IV : apport du Cis-Platinum et de l’Adriamycine. Symposium AFEC sur les cancers de l’ovaire, 1983 (Abst.), Paris.

179. D. BELPOMME , H. GAUTIER, E. PUJADE-LAURAINE, L. MIGNOT, M. MARTY, M. BOIRON. Cis-platinum et cancers bronchiques épidermoïdes évolués : apport des combinaisons COPAB et COPAC. 2ème Forum de Cancérologie (AFEC), 1982, 19 (Abst.), Paris.

180. D. BELPOMME , H. GAUTIER, E. PUJADE-LAURAINE, et al. CCNU ©, Vincristine (O), DDP (P), Adriamycin (A), containing combination chemotherapy in advanced squamous cell bronchus carcinoma. Proc. ASCO, 1982 (Abst.), Seattle, USA.

181. J.L. MISSET, M. DELGADO, R. PLAGNE, D. BELPOMME , et al. Three years results of a randomized trial comparing CMF to Adriamycin (A), Vincristine (VCR), Cyclophosphamide (AVCR) as adjuvant therapy of operated N+ breast cancer. A “Group Inter France trial”. Proc. American Society of Clinical Oncology, 1982, 1: 84 (Abst. 325), Seattle, USA.

182. R. PLAGNE, J.L. MISSET, D. BELPOMME , et al. BCG adjuvant immunotherapy after adjuvant chemotherapy for operable breast cancer. A “Group Inter France randomized trial. Proc. Amer. Assoc. Cancer Res. 1982, 23: 156 (Abst. 615).

183. C. GISSELBRECHT, D. BELPOMME , L. MIGNOT, E. PUJADE-LAURAINE, F. MORVAN, M. MARTY, M. BOIRON. A phase II trial of 5-FU, Adriamycin and Cisplatin (FAP) in advanced oesophaghus carcinomas. Proc. 7th Annual Meeting ESMO, 1981, p. 105 (Abst. 12-123), Lausanne.

184. G. MATHE, J.L. MISSET, F. DE VASSAL, M. DELGADO, R. PLAGNE, D. BELPOMME , et al (Group Inter-France). Adjuvant (A) chemotherapy (C) including Adriamycin (ADM) in operable breast carcinoma. Preliminary results of a phase III trial. Proc. 7th Annual Meeting ESMO, 1981, p. 34 (Abst. 03-0508), Lausanne.

185. E. PUJADE-LAURAINE, D. BELPOMME , L. MIGNOT, A. LE ROL, A. BOHU, M. GRANDJEAN, C. GISSELBRECHT, M. MARTY, M. BOIRON. Metastatic breast cancer: individualisation of groups of patients with different chemosensitivity. Proc. 7th Annual Meeting ESMO, 1981, p. 30 (Abst. 03-0289), Lausanne.

186. E. PUJADE-LAURAINE, L. MIGNOT, D. BELPOMME , M. ESPIE, C. GISSELBRECHT, M. MARTY, M. BOIRON. Phase II trial of intermediate dose of Methotrexate, Adriamycin, Mitomycin C (MAM) in advanced breast cancer. Proc. 7th Annual Meeting ESMO, 1981, p. 29 (Abst. 3-254).

187. LE ROL, D. GANEVAL, D. BELPOMME , A. BOHU, E. PUJADE-LAURAINE, M. MARTY, M. BOIRON. Caracterization of Mitomycin-C induced glomerulopathy: a 2 cases study. Proc. 7th Annual Meeting ESMO, 1981, p. 111 (Abst. 12-533).

188. D. BELPOMME , H. GAUTIER, E. PUJADE-LAURAINE, C. NEUMAN, C. GISSELBRECHT, L. MIGNOT, A. LEROL, F. MORVAN, M. MARTY, M. BOIRON. CCNU ©, Vincristine (O), Cisplatinum (P), Adriamycin (A), containing combination chemotherapy in advanced epidermoimd and large cell undifferentiated lung carcinoma. Proc. 7th Annual Meeting ESMO, 1981, p. 22 (Abst. 2-234).

189. L. MIGNOT, A. DE ROQUANCOURT, A. GORINS, D. BELPOMME, C. GISSELBRECHT, M. MARTY, M. BOIRON. Clinical and histopathologic findings after induction hormono-chemotherapy in inflammatory breast cancer. Proc. ASCO, 1981, 22: 442 (Abst. 430).

30

190. E. PUJADE-LAURAINE, D. BELPOMME , M. HENRI-AMAR, B. CAILLOU, A.J.S. DAVIES, P. BOIVIN, M. BOIRON, G. MATHE. Prognostic value of lymphoid differentiation markers in B cell non-Hodgkin lymphoma. Proc. 6th Annual Meeting ESMO, 1980, 10: 40 (Abst. 159), Nice.

191. J.L. MISSET, F. CALVO, D. PONTVERT, D. BELPOMME , G. MATHE. Lymphoblastic lymphoma (lymphosarcoma). Proc. 6th Annual Meeting ESMO, 1980, 10: 35 (Abst. 137), Nice.

192. L. MIGNOT, A. de ROQUANCOURT, A. GORINS, D. BELPOMME , C. GISSELBRECHT, M. MARTY, M. BOIRON. Pathological modifications of breast tissue after hormono-chemotherapy in inflammatory breast cancer. Proc. 6th Annual Meeting ESMO, 1980, 10: 34 (Abst. 133), Nice.

193. M. GRANDJEAN, D. BELPOMME , E. PUJADE-LAURAINE, M. MARTY, M. BOIRON. Prevention of drug-induced alopecia in cancer patients. Proc. 6th Annual Meeting ESMO, 1980, 10: 22 (Abst. 85), Nice.

194. C. GISSELBRECHT, L. MIGNOT, D. BELPOMME , A. GORINS, M. MARTY, M. BOIRON. Evaluation of the association hexamethylmelamine (HMM), Adriamycin and Prednisone in advanced breast cancer. Proc. 6th Annual Meeting ESMO, 1980, 10: 20 (Abst. 78), Nice.

195. C. GISSELBRECHT, F. LOKIEC, M. MARTY, L. MIGNOT, D. BELPOMME , Y. NAJEAN, M. BOIRON. Adriamycin pharmacokinetics and abnormal liver function tests. Proc. 6th Annual Meeting ESMO, 1980, 10: 4 (Abst. 16), Nice.

196. D. BELPOMME , E. PUJADE-LAURAINE, C. GISSELBRECHT, L. MIGNOT, M. GRANDJEAN, P. BOUFFETTE, A. BOHU, M. MARTY, M. BOIRON. Bronchus small cell anaplastic carcinoma : treatment of extensive disease by Adriamycin, Vincristine, Methotrexate, Cyclophosphamide and radiotherapy. Proc. 6th Annual Meeting ESMO, 1980, 10: 4 (Abst. 16), Nice.

197. D. BELPOMME , C. GISSELBRECHT, L. MIGNOT, M. MARTY, M. BOIRON. Pilot studies for carcinomas of the digestive tract. Proc. 6th Annual Meeting ESMO, 1980, 10: 4 (Abst. 15), Nice.

198. C. GISSELBRECHT, D. BELPOMME , L. MIGNOT, M. MARTY, G. MATHE, M. BOIRON. Chemotherapy for carcinomas of the digestive tract. In the book "Recent results in cancer research" (G. BONADONNA, G. MATHE, S. SALMON, Eds), Springer Verlag Ed., 1980, Heidelberg.

199. E. PUJADE-LAURAINE, D. BELPOMME . Human non Hodgkin lymphoma: a model of cellular differentiation. In the book "Human lymphocytes differenciation: its application to cancer", INSERM Symposium (B. SERROU, C. ROSENFELD, Eds), 1980, pp. 301-321, Douin.

200. E. PUJADE-LAURAINE, C. GION, A. BOHU, D. BELPOMME . Réévaluation of CEA in cancer: a computered study of 790 cases. Proc. 5th Annual Meeting ESMO, 1979 (Abst.), Nice.

201. G. MATHE, L. SCHWARZENBERG, F. DE VASSAL, M. DELGADO, J. PENA-ANGULO, D. BELPOMME , et al. Chemotherapy followed by active immunotherapy in the treatment of actue lymphoid leukemias for patients of all ages: results of ICIG acute lymphoid leukemia protocols 1, 9 and 10 ; pronostic factors, and therapeutic implications. In the book "Immunotherapy of Cancer", Raven Press, 1978, pp. 451-469.

202. D. BELPOMME , B. CAILLOU, N. LELARGE, I. BOTTO, E. PUJADE-LAURAINE, L. DENARDO, R. GERARD-MARCHANT, A.J.S. DAVIES, G. MATHE. Categorization of non-Hodgkin’s hematosarcomas (lymphomas) according to T - and B - Cell markers: its value for diagnosis and prognosis. In the book "Recent results in Cancer research", Springer Verlag Ed., 1978, vol. 64, pp. 146-157, Heidelberg.

203. D. BELPOMME , F. SIMON, P. POUILLART, B. AMOR, F. FEUILHADE DE CHAUVIN, A. BELPOMME, C. MENKES, A. DELRIEU, R. DEPIERRE, B. LE MEVEL. Prognostic factors and treatment of multiple myeloma: interest of a cyclic sequential chemohormonotherapy combining Cyclophos-phamide, Melphalan and Prednisone. In the book "Recent results in Cancer research" (G. MATHE, M. SELIGMANN, M. TUBIANA), Springer Verlag Ed., 1978, vol. 65, pp. 25-40, Heidelberg.

204. D. BELPOMME , L. DE LUCA, C. BAYLE-WESGERGER, et al. Cytological, Immunological and clinical prognostic parameters in the classification of chronic lymphoid leukemias (CLL): a retrospective survey based on 120 cases. Proc. 3rd Annual Meeting ESMO, 1977 (Abst. 31), Nice.

205. D. BELPOMME , G. MATHE, A.J.S. DAVIES. Immunological markers as prognostic parameters in acute lymphoid leukemia (ALL) and non-Hodgkin’s malignant lymphoma. 8th International Symposium on comparative research on leukemia and related diseases, August 1977 (Abst.), Amsterdam.

206. G. MATHE, F. DE VASSAL, L. SCHWARZENBERG, M.A. BIL, M. DELGADO, R. WEINER, J. PENA-ANGULO, D. BELPOMME , et al. Results in children of acute lymphoid leukemia: protocol ICIG-ALL9 consisting of chemotherapy for only 9 months followed by active immunotherapy. In the book "Recent results in Cancer research", Springer Verlag Ed., vol. 62, pp.67-77, 1977, Paris.

207. G. MATHE, F. DE VASSAL, L. SCHWARZENBERG, M.A. GIL, M. DELGADO, R. WEINGER, J. PENA-ANGULO, D. BELPOMME , et al. Comparison of the results of three chemo-immunotherapy

31

protocols for the treatment of acute lymphoid leukemia of children. In the book "Advances in comparative leukemia research 1977", Elsevier/North-Holland Biomedical press, 1977, pp. 408-413.

208. J.L. MISSET, P. POUILLART, J.L. AMIEL, L. SCHWARZENBERG, M. HAYAT, F. DE VASSAL, M. MUSSET, D. BELPOMME , C. JASMIN, G. MATHE. Combinaison d’Adriamycine, de VM26, de Cyclosphosphamide et de Prednisone (AVmCP) pour le traitement des lymphosarcomes et réticulosarcomes de stade III et IV. 3ème Congrès français d’hématologie, 1977 (Abst.), Brussels.

209. G. MATHE, D. BELPOMME , D. DANTCHEV, et al. Les lymphosarcomes immunoblastiques : une entité cytologique et clinique ? 3ème Congrès français d’hématologie, 1977 (Abst.), Brussels.

210. J.L. MISSET, F. DE VASSAL, M. HAYAT, D. MACHOVER, D. BELPOMME , L. SCHWARZENBERG, P. RIBAUD, et al. Phase II clinical trial with Vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma and Hodgkin’s disease. Absence of cross resistance with Vincristine. Proc. 3rd Annual Meeting ESMO, 1977 (Abst. 51), Nice.

211. MATHE, M. HAYAT, F. DE VASSAL, J.L. MISSET, L. SCHWARZENBERG, D. MACHOVER, P. RIBAUD, D. BELPOMME , et al. Preliminary results of phase I and II clinical trials of RFCNU and RPCNU, two new nitrosouera sugar derivatives in digestive tract tumors. Proc. 3rd Annual Meeting ESMO, 1977 (Abst. 47), Nice.

212. D. BELPOMME , A. BOHU, F. FEKETE, J.M. KRIVINE, F. BERNARD, G. MATHE. Chemotherapy and chemo-immuno-therapy of gastrointestinal tumors. 1st Symposium on experimental approaches to the treatment of gastrointestinal tumors, 1977 (Abst.), Brussels.

213. D. BELPOMME , G. MATHE. Chimiothérapie et immunothérapie des cancers de l’estomac et du côlon. Conférence d’Enseignement National Post-universitaire de gastro-entérologie, 1977 (Abst.), Strasbourg.

214. BOHU, D. BELPOMME , M. MUSSET, E. GARCIA-GIRALT. Chemotherapy combination and chemo-immunotherapy in advanced gastro-intestinal tumors. Proc. 3rd Annual Meeting ESMO, 1977 (Abst. 101), Nice.

215. D. BELPOMME , Z. HADDAR, P. POUILLART, J.L. MISSET, et al. Chemotherapy and chemo-immunotherapy of disseminated breast cancers: preminary results of two trials. Proc. 3rd Annual Meeting ESMO, 1977 (Abst. 97), Nice.

216. D. BELPOMME , J.L. MISSET, G. MATHE. Correlation of results of a chemo-radio-immunotherapy protocol in stage III and IV lymphosarcoma and reticulosarcoma with histocytological W.H.O. classification and immune marker categorisation. Proc. 3rd Annual Meeting ESMO, 1977 (Abst. 95), Nice.

217. D. BELPOMME . Immunologic markers of non-Hodgkin lymphomas. Antigenic markers of acute lymphoid leukemia and of blast cells in chronic myeloid leukemia. Colloque International du CNRS sur les néoplasies lymphoïdes (G. MATHE, M. SELIGMANN, M. TUBIANA, Eds), 1977, Paris.

218. D. BELPOMME , G. MATHE. The prognostic value of the immunological classification of acute lymphoid leukemias and lymphosarcoma. International Symposium on "Recent trends in the immunological diagnosis of leukemias and lymphomas", October 1976 (Abst.), Munich.

219. D. BELPOMME , D. DANTCHEV, R. JOSEPH, A. SANTORO, N. LELARGE, F. FEUILHADE DE CHAUVIN, D. GRANDJON, G. MATHE. Cell membrane markers of T and B lymphocytes and monocytes in leukemias an hematosarcomas. In the book "Biological characterization of human tumors", 1976, vol. 1, pp. 357-366, Amsterdam.

220. D. BELPOMME , D. DANTCHEV, R. JOSEPH, A. SANTORO, P. FEUILHADE DE CHAUCIN, N. LELARGE, D. GRANDJON, D. PONVERT, G. MATHE. Classification of leukemias and hematosarcomas based on cell membrane markers and scanning electron microscopy. In the book "Clinical tumor immunology", J. Wybran Ed., Pergamon Press, 1976, vol. 1, pp. 131-144, Oxford.

221. D. BELPOMME , N. LELARGE, Caractérisation immunologique et cytochimique des lymphocytes et monocytes. Nécessité d’une batterie de tests. In the book "Techniques de séparation et d’identification des lymphocytes humains", INSERM Ed., 1976, vol. 57, pp. 75-88, Paris.

222. D. BELPOMME , N. LELARGE, F. FEUILHADE DE CHAUVIN, R. JOSEPH, G. MATHE. An immunological classification of leukemias and hematosarcomas based on cell membrane markers with special reference to null cell disorders. In the book "Lymphocytes, Macrophages and cancer" (G. MATHE, I. FLORENTIN, M.C. SIMMLER, Eds), Springer Verlag Ed., 1976, pp. 98-110, Heidelberg.

223. R. JOSEPH, D. BELPOMME . Increase in "null" cells in acute lymphocytic leukemia in remission on long-term immunotherapy. In the book "Lymphocytes, Macrophages and cancer" (G. MATHE, I. FLORENTIN, M.C. SIMMLER, Eds.), Springer Verlag Ed., 1976, pp. 72-78, Heidelberg.

224. D. BELPOMME , D. DANTCHEV, A.M. KARIMA, N. LELARGE, R. JOSEPH, B. CAILLOU, N. LAFLEUR, G. MATHE. Search for correlations between immunological and morphological criteria used to classify lymphoid leukaemias and non-Hodgkin’s hematosarcomas witih special reference to scanning electron microscopy and T and B membrane markers. In the book "Lymphocytes, Macrophages and

32

Cancer" (G. MATHE, I. FLORENTIN, M.C. SIMMLER, Eds.), Springer Verlag Ed., 1976, pp. 131-143, Heidelberg.

225. MATHE, D. BELPOMME , D. DANTCHEV, P. POUILLART. Les récents progrès réalisés dans la classification des leucémies lymphoïdes et monocytoïdes et des lympho et réticulosarcomes. Mémoire Société Médicale des hôpitaux de Paris, 1975, pp. 523-534, Paris.

226. D. BELPOMME , R. JOSEPH, D. DANTCHEV, P. GRANDJON, G. MATHE. Cell membrane markers of T and B lymphocytes in leukemias and hematosarcomes. In the "Table Ronde Roussel UCLAF", 1975, pp.46-63, Paris.

227. D. BELPOMME , D. DANTCHEV, R. JOSEPH, R. HUCHET, D. GRANDJON, A. SANTORO, G. MATHE. Further studies of acute and chronic leukemias: T and B cell membrane markers and scanning electron microscopy. In the book "Current studies on standardisation problems in clinical pathology haematology and radiotherapy in Hodgkin’s disease", Exerpta Medica, 1975, pp. 143-155, Amsterdam.

228. MATHE, D. BELPOMME , D. DANTCHEV, P. POUILLART. A proposed classification of lymphatic and/or monocytoid malignant neoplasia. In the book "Current studies on standardization problem in clinical pathology haematology and radiotherapy in Hodgkin’s disease", Excerpta Medica, 1975, pp. 118-129, Amsterdam.

229. D. BELPOMME , G. MATHE, P. POUILLART, G. HAUSS, A. MACIEIRA-COELHO. Statistical study of the prognostic factors of acute lymphoid leukemia. Proc. American Assoc. Cancer Res., 1975, 16: 58.

230. P. POUILLART, L. SCHWARZENBERG, J.L. AMIEL, D. BELPOMME , M. HAYAT, H. RAPPAPORT. Prognostic factors in acute lymphoid leukemias. Exp. Hematol., 1974, 2: 283.

231. D. BELPOMME , D. DANTCHEV, P. POUILLART, L. SCHWARZENBERG, J.L. AMIEL, H. RAPPAPORT, G. MATHE. T and B lymphocyte markers on the cells of acute and chronic leukaemias. Exp. Hematol., 1974, 2: 283.

232. D. BELPOMME , P. CARDE, R.K. OLDHAM, G. MATHE, C. JACQUILLAT, N. CHELLOUL, M. WEIL, C. AUCLERC, C. WEISBERGER, J. TANZER, J. BERNARD. Malignancies possibly secondary of anticancer therapy. In the book "Complications of Cancer Chemotherapy", Recent Results in Cancer Research, Springer Verlag Ed., 1974, vol.49, pp. 115-123, Heidelberg.

233. P. POUILLART, G. MATHE, L. SCHWARZENBERG, D. BELPOMME , J.L. AMIEL, H. RAPPAPORT, M. HAYAT. Prognostic factors in acute lymphoid leukemia (ALL) patients treated by active immunotherapy. Proc. American Assoc. Cancer Res., 1974, 15: 75.

234. D. BELPOMME , G. MATHE. Les cancers d’origine thérapeutique. 38ème Congrès Français de Médecine, 1971, Beyrouth, Lebanon.

235. J.F. DORE, L. MARHOLEV, E. AJURIA, D. BELPOMME , G. MATHE. Serological evidence for immune reaction to leukemia in man. 13rd International Congress Haematol., 1970, 276 (Abst.), Munich.

236. C. TREBUCHET, CH. LEBORGNE DE KAOUEL, C. FINAZ, C. TURLEAU, D. BELPOMME , J. DE GROUCHY. Etudes cytogénétiques de six lignées cellulaires continues. Congrès International de génétique, 1969, 178 (Abst. 647), Paris.